Cover
Cover - USD ($) | 12 Months Ended | ||
Dec. 31, 2021 | Apr. 15, 2022 | Jun. 30, 2021 | |
Cover [Abstract] | |||
Document Type | 10-K | ||
Amendment Flag | false | ||
Document Annual Report | true | ||
Document Transition Report | false | ||
Document Period End Date | Dec. 31, 2021 | ||
Document Fiscal Period Focus | FY | ||
Document Fiscal Year Focus | 2021 | ||
Current Fiscal Year End Date | --12-31 | ||
Entity File Number | 000-32141 | ||
Entity Registrant Name | NUTRA PHARMA CORP. | ||
Entity Central Index Key | 0001119643 | ||
Entity Tax Identification Number | 91-2021600 | ||
Entity Incorporation, State or Country Code | CA | ||
Entity Address, Address Line One | 1537 NW 65th Ave | ||
Entity Address, City or Town | Plantation | ||
Entity Address, State or Province | FL | ||
Entity Address, Postal Zip Code | 33313 | ||
City Area Code | (954) | ||
Local Phone Number | 509-0911 | ||
Entity Well-known Seasoned Issuer | No | ||
Entity Voluntary Filers | No | ||
Entity Current Reporting Status | Yes | ||
Entity Interactive Data Current | Yes | ||
Entity Filer Category | Non-accelerated Filer | ||
Entity Small Business | true | ||
Entity Emerging Growth Company | false | ||
Entity Shell Company | false | ||
Entity Public Float | $ 5,755,920 | ||
Entity Common Stock, Shares Outstanding | 7,363,852,214 | ||
Auditor Name | Rotenberg Meril Solomon Bertiger & Guttilla, PC | ||
Auditor Location | Saddle Brook, NJ | ||
Auditor Firm ID | 361 |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) | Dec. 31, 2021 | Dec. 31, 2020 |
Current assets: | ||
Cash | $ 90,910 | |
Accounts receivable | 45,998 | 37,080 |
Inventory, current portion | 31,289 | 5,271 |
Other receivable | 6,000 | 3,000 |
Convertible notes receivable | 273,480 | |
Prepaid expenses and other current assets | 86,150 | 10,000 |
Total current assets | 533,827 | 55,351 |
Inventory, less current portion | 98,880 | 78,880 |
Property and equipment, net | 44,701 | 14,742 |
Operating lease right-of-use assets | 93,811 | 144,010 |
Security deposit | 8,803 | 8,803 |
Total assets | 780,022 | 301,786 |
Current liabilities: | ||
Accounts payable | 672,372 | 599,428 |
Accrued expenses | 851,470 | 780,432 |
Accrued payroll due to officers | 1,053,693 | 1,429,693 |
Accrued interest to related parties | 147,768 | 179,522 |
Due to officer | 199,726 | 200,837 |
Derivative liabilities | 10,537,344 | 3,567,176 |
Other debt, net of discount, current portion | 7,598,325 | 4,631,921 |
SBA notes payable, current portion | 2,121 | 10,725 |
Operating lease obligations, current portion | 77,673 | 82,873 |
Total current liabilities | 21,140,492 | 11,482,607 |
Convertible notes, less current portion | 369,401 | 48,477 |
SBA notes payable, less current portion | 147,779 | 204,070 |
Operating lease obligations, less current portion | 60,447 | |
Total liabilities | 21,657,672 | 11,795,601 |
Commitments and Contingencies | ||
Stockholders’ deficit: | ||
Common stock, $0.001 par value, 12,000,000,000 and 8,000,000,000 shares authorized: 7,330,985,964 and 6,955,197,214 shares issued and outstanding at December 31, 2021 and 2020 | 7,330,986 | 6,955,197 |
Additional paid-in capital | 53,508,353 | 50,181,456 |
Accumulated deficit | (81,728,989) | (68,633,468) |
Total stockholders’ deficit | (20,877,650) | (11,493,815) |
Total liabilities and stockholders’ deficit | 780,022 | 301,786 |
Series A Preferred Stock [Member] | ||
Stockholders’ deficit: | ||
Preferred stock, value | 3,000 | |
Series B Preferred Stock [Member] | ||
Stockholders’ deficit: | ||
Preferred stock, value | $ 12,000 |
Consolidated Balance Sheets (Pa
Consolidated Balance Sheets (Parenthetical) - $ / shares | Dec. 31, 2021 | Dec. 31, 2020 |
Common stock, par value | $ 0.001 | $ 0.001 |
Common stock, shares authorized | 12,000,000,000 | 8,000,000,000 |
Common stock, shares issued | 7,330,985,964 | 6,955,197,214 |
Common Stock, Shares, Outstanding | 7,330,985,964 | 6,955,197,214 |
Series A Preferred Stock [Member] | ||
Preferred stock, par value | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized | 0 | 20,000,000 |
Preferred stock, shares issued | 0 | 3,000,000 |
Preferred stock, shares outstanding | 0 | 3,000,000 |
Series B Preferred Stock [Member] | ||
Preferred stock, par value | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized | 20,000,000 | 0 |
Preferred stock, shares issued | 12,000,000 | 0 |
Preferred stock, shares outstanding | 12,000,000 | 0 |
Consolidated Statements of Oper
Consolidated Statements of Operations - USD ($) | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Income Statement [Abstract] | ||
Net sales | $ 97,735 | $ 51,897 |
Cost of sales | (41,268) | (15,678) |
Change in reserve for supplier advances for purchases | (48,000) | (21,303) |
Gross profit | 8,467 | 14,916 |
Operating expenses: | ||
Selling, general and administrative - including stock based compensation of $153,500 and $8,500 for the years ended December 31, 2021 and 2020, respectively | 1,928,582 | 1,101,363 |
Bad debt expense (recovery) -related party | 68,330 | (161,500) |
Total operating expenses | 1,996,912 | 939,863 |
Loss from operations | (1,988,445) | (924,947) |
Other income (expenses) | ||
Other income | 78,254 | 5,000 |
Interest expense | (477,433) | (316,207) |
Interest expense to related parties | (18,246) | (19,967) |
Change in fair value of convertible notes and derivatives | (10,096,315) | (1,012,556) |
Stock based loan modification cost | (107,500) | (87,800) |
(Loss) gain on settlement of debt and accrued expense, net | (485,836) | 1,587,293 |
Total other income (expenses) | (11,107,076) | 155,763 |
Loss before income taxes | (13,095,521) | (769,184) |
Provision for income taxes | ||
Net loss | $ (13,095,521) | $ (769,184) |
Net loss per share - basic and diluted | $ 0 | $ 0 |
Weighted average number of shares outstanding during the year - basic and diluted | 7,232,591,111 | 6,607,482,758 |
Consolidated Statements of Op_2
Consolidated Statements of Operations (Parenthetical) - USD ($) | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Income Statement [Abstract] | ||
Stock based compensation | $ 153,500 | $ 8,500 |
Consolidated Statements of Chan
Consolidated Statements of Changes in Stockholders' Deficit - USD ($) | Preferred Stock [Member]Series A Preferred Stock [Member] | Preferred Stock [Member]Series B Preferred Stock [Member] | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | Total |
Balance at Dec. 31, 2019 | $ 3,000 | $ 5,876,746 | $ 50,283,503 | $ (67,864,284) | $ (11,701,035) | |
Balance, shares at Dec. 31, 2019 | 3,000,000 | 5,876,746,111 | ||||
Common stock issued for debt modification and penalty | $ 138,500 | (50,700) | 87,800 | |||
Common stock issued for debt modification and penalty, shares | 138,500,000 | |||||
Common stock issued for conversion of debt | $ 814,951 | (13,847) | 801,104 | |||
Common stock issued for conversion of debt, shares | 814,951,103 | |||||
Common stock issued for settlement of debt | $ 125,000 | (37,500) | 87,500 | |||
Common stock issued for settlement of debt, shares | 125,000,000 | |||||
Net loss | (769,184) | (769,184) | ||||
Balance at Dec. 31, 2020 | $ 3,000 | $ 6,955,197 | 50,181,456 | (68,633,468) | (11,493,815) | |
Balance, shares at Dec. 31, 2020 | 3,000,000 | 6,955,197,214 | ||||
Common stock issued for debt modification and penalty | $ 25,000 | 82,500 | 107,500 | |||
Common stock issued for debt modification and penalty, shares | 25,000,000 | |||||
Common stock issued for conversion of debt | $ 240,350 | 2,104,049 | 2,344,399 | |||
Common stock issued for conversion of debt, shares | 240,350,000 | |||||
Common stock issued for settlement of debt | $ 62,939 | 472,848 | 535,787 | |||
Common stock issued for settlement of debt, shares | 62,938,750 | |||||
Net loss | (13,095,521) | (13,095,521) | ||||
Exchange of Series A Preferred Stock for Series B Preferred stock | $ (3,000) | $ 3,000 | ||||
Exchange of Series A Preferred Stock for Series B Preferred stock, shares | (3,000,000) | 3,000,000 | ||||
Series B Preferred Stock issued in exchange for accrued salary | $ 9,000 | 531,000 | 540,000 | |||
Series B preferred stock issued in exchange for accrued salary to a related party, shares | 9,000,000 | |||||
Common stock issued in exchange for services to consultants | $ 35,000 | 139,000 | 174,000 | |||
Common stock issued in exchange for services to consultants, shares | 35,000,000 | |||||
Common stock issued in exchange for accrued interest to a related party | $ 12,500 | (2,500) | 10,000 | |||
Common stock issued in exchange for accrued interest to a related party, shares | 12,500,000 | |||||
Balance at Dec. 31, 2021 | $ 12,000 | $ 7,330,986 | $ 53,508,353 | $ (81,728,989) | $ (20,877,650) | |
Balance, shares at Dec. 31, 2021 | 12,000,000 | 7,330,985,964 |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows - USD ($) | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Cash flows from operating activities: | ||
Net loss | $ (13,095,521) | $ (769,184) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Change in reserve for supplier advances for purchases | 48,000 | 21,303 |
Bad debt expense (recovery) - related party | 68,330 | (161,500) |
Accrued interest expense for amount due to officer | 7,520 | 7,675 |
Loss on settlement of debt and accrued expense | 485,836 | (1,587,293) |
Depreciation | 9,084 | 3,831 |
Stock-based compensation | 153,500 | 8,500 |
Stock-based loan modification cost | 107,500 | 87,800 |
Amortization of convertible notes receivable discount | (12,980) | |
Forgiveness of PPP loan | (65,274) | |
Change in fair value of convertible notes and derivatives | 10,096,315 | 1,012,556 |
Amortization of loan discount | 326,391 | 130,485 |
Amortization of operating lease right-of-use assets | 54,301 | 63,520 |
Changes in operating assets and liabilities: | ||
Increase in accounts receivable | (8,920) | (4,601) |
Increase in other receivable | (9,000) | (3,000) |
Increase in inventory | (46,018) | (23,791) |
Increase in prepaid expenses and other current assets | (103,650) | (15,906) |
Increase in accounts payable | 72,944 | 10,297 |
Increase in accrued expenses | 94,676 | 214,235 |
Increase in accrued payroll due to officers | 164,000 | 180,300 |
Increase (decrease) in accrued interest to related parties | (21,754) | 19,967 |
Decrease in operating lease obligations | (69,749) | (73,280) |
Net cash used in operating activities | (1,744,469) | (878,086) |
Cash flows from investing activities: | ||
Convertible notes receivable advances | (254,500) | |
Acquisition of equipment | (39,043) | (5,905) |
Net cash used in investing activities: | (293,543) | (5,905) |
Cash flows from financing activities: | ||
Loans from officer | 105,780 | 254,000 |
Repayment of officer loans | (182,741) | (22,150) |
Repayments of notes payable-related party | (14,400) | |
Proceeds from convertible notes | 2,288,560 | 527,983 |
Repayment of convertible notes | (67,302) | (5,782) |
Advances from an unrelated third party | 50,000 | |
Repayments of other notes payable | (15,375) | (120,455) |
Proceeds from SBA notes payable | 214,795 | |
Net cash provided by financing activities | 2,128,922 | 883,991 |
Net increase in cash | 90,910 | |
Cash - beginning of period | ||
Cash - end of period | 90,910 | |
Supplemental Cash Flow Information: | ||
Cash paid for interest | 42,677 | 1,049 |
Cash paid for income taxes | ||
Non Cash Financing and Investing: | ||
Common stock issued in settlement of notes and accrued expenses | 535,787 | 87,500 |
Common stock issued for conversion of debt | 2,344,399 | 801,104 |
Common stock issued to satisfy accrued interest-related party | 10,000 | |
Preferred stock issued satisfy accrued salary | 540,000 | |
Warrants issued with Debt--Debt discount | 150,000 | 105,000 |
Purchase of equipment included in accounts payable | 5,905 | |
Increase of right-of-use asset due to lease renewal | 4,102 | |
Increase of operating lease liabilities due to lease renewal | 4,102 | |
Reclassification of accrued interest to debt | 30,850 | |
Reclassification of rental receivable to convertible notes receivable | $ 6,000 |
BASIS OF PRESENTATION AND SUMMA
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | 12 Months Ended |
Dec. 31, 2021 | |
Accounting Policies [Abstract] | |
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | 1. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Organization Nutra Pharma Corp. (“Nutra Pharma”), is a holding company that owns intellectual property and operates in the biotechnology industry. Nutra Pharma was incorporated under the laws of the state of California on February 1, 2000, under the original name of Exotic-Bird.com. Through its wholly-owned subsidiary, ReceptoPharm, Inc. (“ReceptoPharm”), Nutra Pharma conducts drug discovery research and development activities. In October 2009, Nutra Pharma launched its first consumer product called Cobroxin ® ® ® Luxury Feet, an over-the-counter pain reliever and anti-inflammatory product that is designed for women who experience pain or discomfort due to high heels and stilettos. In October of 2021 we began manufacturing a zeolite detoxifier called Cell Defender for a third party distributor. Basis of Presentation and Consolidation The accompanying Consolidated Financial Statements include the results of Nutra Pharma and its wholly-owned subsidiaries Designer Diagnostics Inc. and ReceptoPharm (collectively “the Company”, “us”, “we” or “our”). We operate as one reportable segment. Designer Diagnostics Inc. has been inactive since June 2011. All intercompany transactions and balances have been eliminated in consolidation. Liquidity and Going Concern Our Consolidated Financial Statements are presented on a going concern basis, which contemplate the realization of assets and satisfaction of liabilities in the normal course of business. We have experienced recurring, significant losses from operations, and have an accumulated deficit of $ 81,728,989 20,606,665 20,877,650 There is substantial doubt regarding our ability to continue as a going concern which is contingent upon our ability to secure additional financing, increase ownership equity and attain profitable operations. In addition, our ability to continue as a going concern must be considered in light of the problems, expenses and complications frequently encountered in established markets and the competitive environment in which we operate. We do not have sufficient cash to sustain our operations for a period of twelve months from the issuance date of this report and will require additional financing in order to execute our operating plan and continue as a going concern. Since our sales are not currently adequate to fund our operations, we continue to rely principally on debt and equity funding; however, proceeds from such funding have not been sufficient to execute our business plan. Our plan is to attempt to secure adequate funding until sales of our pain products are adequate to fund our operations. We cannot predict whether additional financing will be available, and/or whether any such funding will be in the form of equity, debt, or another form. In the event that these financing sources do not materialize, or if we are unsuccessful in increasing our revenues and profits, we will be unable to implement our current plans for expansion, repay our obligations as they become due and continue as a going concern. The accompanying Consolidated Financial Statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern. Impact of COVID-19 on our Operations The ramifications of the outbreak of the novel strain of COVID-19, reported to have started in December 2019 and spread globally, are filled with uncertainty and changing quickly. Our operations have continued during the COVID-19 pandemic and we have not had significant disruption. Beginning in June 2020, the Company experienced a delay in retail rollout as a downstream implication of the slowing economy. We also closed our Coral Springs office in effort to save money. During May 2020, we received approval from the Small Business Administration (“SBA”) to fund our request for a PPP loan for $ 64,895 150,000 The Company is operating in a rapidly changing environment so the extent to which COVID-19 impacts its business, operations and financial results from this point forward will depend on numerous evolving factors that the Company cannot accurately predict. Those factors include the following: the duration and scope of the pandemic; governmental, business and individuals’ actions that have been and continue to be taken in response to the pandemic; and the distribution of testing and a vaccine. Use of Estimates The accompanying Consolidated Financial Statements are prepared in accordance with accounting principles generally accepted in the United States of America which require management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense. Significant estimates include our ability to continue as going concern, the recoverability of inventories and long-lived assets, the recoverability of amounts due from officer, the valuation of stock-based compensation and certain debt and derivative liabilities, recognition of loss contingencies and deferred tax valuation allowances. Actual results could differ from those estimates. Changes in facts and circumstances may result in revised estimates, which would be recorded in the period in which they become known. Revenue from Contracts with Customers The Company accounts for revenue from contracts with customers in accordance with Financial Accounting Standard Board (“FASB”) Accounting Standard Codification (“ASC”) Topic 606, Revenue from Contracts with Customers Our revenues are primarily derived from customer orders for the purchase of our products. We recognize revenues as performance obligations are fulfilled upon shipment of products. We record revenues net of promotions and discounts. For certain product sales to a distributor, we record revenue including a portion of the cash proceeds that is remitted back to the distributor. Accounting for Shipping and Handling Costs We account for shipping and handling as fulfilment activities and record amounts billed to customers as revenue and the related shipping and handling costs as cost of sales. Accounts Receivable and Allowance for Doubtful Accounts We grant credit without collateral to our customers based on our evaluation of a particular customer’s credit worthiness. Accounts receivable are due 30 days after the issuance of the invoice. In addition, allowances for doubtful accounts are maintained for potential credit losses based on the age of the accounts receivable and the results of periodic credit evaluations of our customers’ financial condition. Accounts receivable are written off after collection efforts have been deemed to be unsuccessful. Accounts written off as uncollectible are deducted from the allowance for doubtful accounts, while subsequent recoveries are netted against the provision for doubtful accounts expense. We generally do not charge interest on accounts receivable. We use third party payment processors and are required to maintain reserve balances, which are included in accounts receivable. Accounts receivable are stated at estimated net realizable value. Accounts receivable are comprised of balances due from customers net of estimated allowances for uncollectible accounts. No Inventories Inventories, which are stated at the lower of average cost or net realizable value, consist of packaging materials, finished products, and raw venom that is utilized to make the API (active pharmaceutical ingredient). The raw unprocessed venom has an indefinite life for use. Commencing on October 1, 2019, we classify inventory as short-term or long-term inventory based on timing of when it is expected to be consumed. The Company regularly reviews inventory quantities on hand. If necessary, it records a net realizable value adjustment for excess and obsolete inventory based primarily on its estimates of product demand and production requirements. Write-downs are charged to cost of goods sold. We performed an evaluation of our inventory and related accounts at December 31, 2021 and 2020, and increased the reserve on supplier advances for future venom purchases included in prepaid expenses and other current assets by $ 48,000 21,303 294,162 246,162 Financial Instruments and Concentration of Credit Risk Our financial instruments include cash, accounts receivable, accounts payable, accrued expenses, loans payable, due to officers and derivative financial instruments. Other than certain warrant and convertible instruments (derivative financial instruments) and liabilities to related parties (for which it was impracticable to estimate fair value due to uncertainty as to when they will be satisfied and a lack of similar type transactions in the marketplace), we believe the carrying values of our financial instruments approximate their fair values because they are short term in nature or payable on demand. Our derivative financial instruments are carried at a measured fair value. Balances in various cash accounts may at times exceed federally insured limits. We have not experienced any losses in such accounts. We do not hold or issue financial instruments for trading purposes. In addition, for the year ended December 31, 2021, there was one customer that accounted for 21 37 100 Operating Lease Right-of-Use Asset and Liability The Company accounts for leases in accordance with Accounting Standards Update (“ASU”) 2016-02, Leases In accordance with ASC Topic 842, at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present and the classification of the lease including whether the contract involves the use of a distinct identified asset, whether we obtain the right to substantially all the economic benefit from the use of the asset, and whether we have the right to direct the use of the asset. Leases with a term greater than one year are recognized on the balance sheet as ROU assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less under practical expedient in paragraph ASC 842-20-25-2. Lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected lease term. The implicit rate within our operating leases are generally not determinable and, therefore, the Company uses the incremental borrowing rate at the lease commencement date to determine the present value of lease payments. The determination of the Company’s incremental borrowing rate requires judgment. The Company determines the incremental borrowing rate for each lease using our estimated borrowing rate. Derivative Financial Instruments Management evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported as charges or credits to income. For option-based simple derivative financial instruments, the Company uses the Black-Scholes option-pricing model to value the derivative instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date. We do not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. Convertible Debt For convertible debt that does not contain an embedded derivative that requires bifurcation, the conversion feature is evaluated to determine if the rate of conversion is below market value and should be categorized as a beneficial conversion feature (“BCF”). A BCF related to debt is recorded by the Company as a debt discount and with the offset recorded to equity. The related convertible debt is recorded net of the discount for the BCF. The discount is amortized as additional interest expense over the term of the debt with the resulting debt discount being accreted over the term of the note. The Fair Value Measurement Option We have elected the fair value measurement option for convertible debt with embedded derivatives that require bifurcation, and record the entire hybrid financing instrument at fair value under the guidance of ASC Topic 815, Derivatives and Hedging Derivative Accounting for Convertible Debt and Options and Warrants The Company evaluated the terms and conditions of the convertible debt under the guidance of ASC 815, Derivatives and Hedging Embedded Derivatives Property and Equipment Property and equipment is recorded at cost. Expenditures for major improvements and additions are added to property and equipment, while replacements, maintenance and repairs which do not extend the useful lives are expensed. Depreciation is computed using the straight-line method over the estimated useful lives of the assets of 3 7 Long-Lived Assets The carrying value of long-lived assets is reviewed annually and on a regular basis for the existence of facts and circumstances that may suggest impairment. If indicators of impairment are present, we determine whether the sum of the estimated undiscounted future cash flows attributable to the long-lived asset in question is less than its carrying amount. If less, we measure the amount of the impairment based on the amount that the carrying value of the impaired asset exceeds the discounted cash flows expected to result from the use and eventual disposal of the impaired assets. Income Taxes We compute income taxes in accordance with FASB ASC Topic 740, Income Taxes On an annual basis, we evaluate tax positions that have been taken or are expected to be taken in our tax returns to determine if they are more than likely to be sustained if the taxing authority examines the respective position. At December 31, 2021 and 2020, we do not believe we have a need to record any liabilities for uncertain tax positions or provisions for interest or penalties related to such positions. Stock-Based Compensation We account for stock-based compensation in accordance with FASB ASC Topic 718, Stock Compensation Net Loss Per Share Net loss per share is calculated in accordance with ASC Topic 260, Earnings per Share SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF NET LOSS PER SHARE 31-Dec-21 31-Dec-20 Options and warrants 446,703,571 202,775,000 Convertible notes payable at fair value 1,427,853,386 1,515,706,865 Convertible notes payable 4,913,379,125 2,814,694,508 Total 6,787,936,082 4,533,176,373 Recent Accounting Pronouncements In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326) In August 2020, the FASB issued ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity In May 2021, the FASB issued ASU No. 2021-04, Earnings Per Share (Topic 260), Debt – Modifications and Extinguishments (Subtopic 470-50), Compensation – Stock Compensation (Topic 718), and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modification or Exchanges of Freestanding Equity-Classified Written Call Options (“ASU 2021-04”), which will clarify and reduce diversity in practice. Specifically, the new standard includes a recognition model comprising four categories of transactions and corresponding accounting treatment for each category. The category that would apply to a modification or an exchange of an equity-classified warrant would depend on the substance of the modification transaction (e.g. a financing transaction to raise equity versus one to raise debt). This recognition model is premised on the idea that the accounting for the transaction should not differ from what it would have been had the issuer of the warrants paid cash instead of modifying the warrants. ASU 2021-04 will be effective for fiscal years beginning after December 15, 2021 and interim periods within those fiscal years. This ASU will be applied prospectively to modifications or exchanges occurring on or after the effective date of the ASU. The Company is currently evaluating the impact this new guidance will have on its consolidated financial statements. All other newly issued accounting pronouncements but not yet effective have been deemed either immaterial or not applicable. |
FAIR VALUE MEASUREMENTS
FAIR VALUE MEASUREMENTS | 12 Months Ended |
Dec. 31, 2021 | |
Fair Value Disclosures [Abstract] | |
FAIR VALUE MEASUREMENTS | 2. FAIR VALUE MEASUREMENTS Certain assets and liabilities that are measured at fair value on a recurring basis at December 31, 2021 and 2020 are measured in accordance with FASB ASC Topic 820-10-05, Fair Value Measurements The statement requires fair value measurement be classified and disclosed in one of the following three categories: Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical unrestricted assets or liabilities; Level 2: Quoted prices in markets that are not active or inputs which are observable either directly or indirectly for substantially the full term of the asset or liability; and Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity). The following table summarizes our financial instruments measured at fair value at December 31, 2021 and December 31, 2020: SUMMARY OF FINANCIAL INSTRUMENTS MEASURED AT FAIR VALUE Fair Value Measurements at December 31, 2021 Liabilities: Total Level 1 Level 2 Level 3 Warrant liability $ 710,585 $ - $ - $ 710,585 Derivative liabilities $ 9,826,759 $ - $ 9,826,759 $ - Convertible notes at fair value $ 2,855,709 $ - $ - $ 2,855,709 Fair Value Measurements at December 31, 2020 Liabilities: Total Level 1 Level 2 Level 3 Warrant liability $ 189,543 $ - $ - $ 189,543 Derivative liabilities $ 3,377,633 $ - $ 3,377,633 $ - Convertible notes at fair value $ 1,832,439 $ - $ - $ 1,832,439 The following table shows the changes in fair value measurements for the warrant liability using significant unobservable inputs (Level 3) during the years ended December 31, 2021 and 2020: SUMMARY OF CHANGES IN FAIR VALUE MEASUREMENTS USING SIGNIFICANT UNOBSERVABLE INPUTS Description 2021 2020 Beginning balance $ 189,543 $ 1,411 Purchases, issuances, and settlements 590,885 143,369 Total loss (gain) included in earnings (1) (69,843 ) 44,763 Total loss (gain) included in earnings (69,843 ) 44,763 Ending balance $ 710,885 $ 189,543 (1) The loss (gain) related to the revaluation of our warrant liability is included in “Change in fair value of convertible notes and derivatives” in the accompanying consolidated statement of operations. We valued our warrants using a Dilution-Adjusted Black-Scholes Model. Assumptions used include (1) 0.19 0.39 273 276 zero We valued derivative liabilities using the number of potential convertible shares for warrants in equity and convertible notes with fixed conversion price that are recorded at amortized cost times the closing stock price of our restricted common stock at December 31, 2021 and 2020, respectively. These derivative liabilities are recorded due to the fact that the number of shares of common stock issuable could exceed the Company’s authorized share limit and the equity environment is tainted, and therefore all convertible debt and options and warrants should be accounted for as liabilities. The following table summarizes assumptions and the significant terms of the convertible notes for which the entire hybrid instrument is recorded at fair value at December 31, 2021 and 2020: SUMMARY OF ASSUMPTIONS AND THE SIGNIFICANT TERMS Conversion Price - Lower of Fixed Debenture Face Interest Default Discount Anti-Dilution % of stock price for look-back period Look-back 2021 $ 762,446 8 10 20 24 N/A $ 0.00050 0.00097 50 60 3 25 2020 $ 766,101 8 10 20 24 N/A $ 0.00050 0.00064 50 60 3 25 Using the stated assumptions summarized in table above, we calculated the inception date and reporting period fair values of each note issued. The following table shows the changes in fair value measurements for the convertible notes at fair value using significant unobservable inputs (Level 3) during the year ended December 31, 2021 and 2020: SUMMARY OF CHANGES IN FAIR VALUE MEASUREMENTS USING SIGNIFICANT UNOBSERVABLE INPUTS Description 2021 2020 Beginning balance $ 1,832,439 $ 5,814,047 Purchases and issuances 132,000 25,981 Day one loss on value of hybrid instrument (1) 2,042,612 318,174 Day one loss on value of hybrid instrument 2,042,612 318,174 Loss (gain) from change in fair value (1) 1,233,538 (1,931,927 Loss (gain) from change in fair value 1,233,538 (1,931,927 Gain on settlement - (1,609,294 Debt discount - 22,344 Repayments in cash (40,480 ) (5,782 ) Conversion to common stock (2,344,399 ) (801,104 ) Ending balance $ 2,855,709 $ 1,832,439 (1) The (gains) losses related to the valuation of the convertible notes are included in “Change in fair value of convertible notes and derivatives” in the accompanying consolidated statement of operations. |
INVENTORIES
INVENTORIES | 12 Months Ended |
Dec. 31, 2021 | |
Inventory Disclosure [Abstract] | |
INVENTORIES | 3. INVENTORIES Inventories are valued at the lower of cost or net realizable value on an average cost basis. At December 31, 2021 and 2020, inventories were as follows: SCHEDULE OF INVENTORIES December 31, 2021 December 31, 2020 Raw Materials $ 126,349 $ 78,880 Finished Goods 3,820 5,271 Total Inventories 130,169 84,151 Less: Long-term inventory (98,880 ) (78,880 ) Current portion $ 31,289 $ 5,271 |
PROPERTY AND EQUIPMENT
PROPERTY AND EQUIPMENT | 12 Months Ended |
Dec. 31, 2021 | |
Property, Plant and Equipment [Abstract] | |
PROPERTY AND EQUIPMENT | 4. PROPERTY AND EQUIPMENT Property and equipment consists of the following at December 31, 2021 and 2020: SCHEDULE OF PROPERTY AND EQUIPMENT December 31, December 31, Computer equipment $ 25,120 $ 25,120 Furniture and fixtures 34,757 34,757 Lab equipment 104,564 65,521 Telephone equipment 12,421 12,421 Office equipment – other 16,856 16,856 Leasehold improvements 73,168 73,168 Total 266,886 227,843 Less: Accumulated depreciation (222,185 ) (213,101 ) Property and equipment, net $ 44,701 $ 14,742 We review our long-lived assets for recoverability if events or changes in circumstances indicate the assets may be impaired. At December 31, 2021, we believe the carrying values of our long-lived assets are recoverable. Depreciation expense for the years ended December 31, 2021 and 2020 was $ 9,084 and $ 3,831 , respectively. |
DUE TO_FROM OFFICER
DUE TO/FROM OFFICER | 12 Months Ended |
Dec. 31, 2021 | |
Related Party Transactions [Abstract] | |
DUE TO/FROM OFFICER | 5. DUE TO/FROM OFFICER At December 31, 2020, the balance due to our President and CEO, Rik Deitsch, was $ 200,837 4 22,150 254,000 7,675 161,500 402,970 At December 31, 2021, the balance due to Rik Deitsch, and the Companies owned by him is $ 199,726 , which is an unsecured demand loan that bears interest at 4 %. During the year ended December 31, 2021, we repaid $ 182,741 to and collected $ 105,780 from Mr. Deitsch and the Companies owned by him. Additionally, accrued interest on the demand loan was $ 7,520 and is included in the due to officer account. For the year ended December 31, 2021, we recorded a bad debt expense of $ 68,330 for the receivables from these Companies |
DEBTS
DEBTS | 12 Months Ended |
Dec. 31, 2021 | |
Debt Disclosure [Abstract] | |
DEBTS | 6. DEBTS Debts consist of the following at December 31, 2021 and 2020: SCHEDULE OF DEBT December 31, 2021 December 31, 2020 Notes payable – Unrelated third parties (Net of discount of $ 0 1,500 $ 1,135,257 $ 1,346,057 Convertible notes payable – Unrelated third parties (Net of discount of $ 283,429 101,448 3,751,760 1,276,902 Convertible notes payable, at fair value (4) 2,855,709 1,832,439 Other advances from an unrelated third party (5) 225,000 225,000 SBA notes payable(6) 149,900 214,795 Ending balances 8,117,626 4,895,193 Less: Long-term portion-Convertible Notes payable-Unrelated third parties (369,401 ) (48,477 ) Less: Long-term portion- SBA notes payable (147,779 ) (204,070 ) Current portion $ 7,600,446 $ 4,642,646 (1) During 2010 we borrowed $ 200,000 nine months interest calculated at 10% for the first month plus 12% December 31, 2016 40,000 12,500,000 10,000 147,768 179,522 18,246 19,967 (2) At December 31, 2021 and 2020, the balance of $ 1,135,257 1,346,057 0 1,500 ● In August 2016, we issued two Promissory Notes for a total of $ 200,000 100,000 12% 101,818 21,023 104,000 88,500 15,500 88,500 91,156 51,856 40,917 The remaining principal balance of $91,156 and accrued interest of $51,856 is being disputed in court and negotiation for settlement ● On August 2, 2011 under a settlement agreement with Liquid Packaging Resources, Inc. (“LPR”), we agreed to pay LPR a total of $ 350,000 50,000 175,000 25,000 25,000 142,858 5,714,326 450,000 350,000 100,000 281,772 281,772 ● At December 31, 2012, we owed University Centre West Ltd. approximately $ 55,410 ● In April 2016, we issued a promissory note to an unrelated third party in the amount of $ 10,000 10% 5,783 4,769 ● In May 2016, the Company issued a promissory note to an unrelated third party in the amount of $ 75,000 2% 5,000,000 25,000 50,000 74,334 62,167 ● In June 2016, the Company issued a promissory note to an unrelated third party in the amount of $ 50,000 2% 50,000 67,534 55,367 ● A promissory note originally issued to an unrelated third party in August 2016 was restated in September 2019 in the amount of $ 333,543 bearing monthly interest at a rate of 2.0% 20,000,000 shares of our common stock. During September 2020, we issued a total of 10,000,000 restricted shares due to the default on repayments. The shares were valued at fair value of $ 6,000 . The common stock was valued at $ 5,895 and recorded as a debt discount that was amortized over the life of the note. Amortization for this debt discount was fully amortized at December 31, 2020. The Note is in default and negotiation of settlement. At December 31, 2021 and 2020, the principal balance is $ 333,543 , and the accrued interest is $ 187,673 and $ 167,216 , respectively. ● On September 26, 2016, we issued a promissory note to an unrelated third party in the amount of $ 75,000 10% 15,000 60,000 15,900 15,000 1,371 ● In October 2016, we issued a promissory note to an unrelated third party in the amount of $ 50,000 2% 63,834 51,667 ● In June 2017, we issued a promissory note to an unrelated third party in the amount of $ 12,500 10% 5,750 4,483 ● During July 2017, we received a loan for a total of $ 200,000 15% 130,401 40,000 5,000 2,000 34,976 42,698 44,478 14,376 33,874 48,250 130,401 33,874 ● In July 2017, we issued a promissory note to an unrelated third party in the amount of $ 50,000 10,000 50,000 ● During September 2018 and 2019, a promissory note originally issued to an unrelated third party in September 2017 was amended in the amount of $ 36,000 6,000 33,000 3,000 7,000 5,000 6,500 1,000 29,500 1,500 1,500 30,000 0.01 12% 1,000 ● During January 2020, a promissory note originally issued to an unrelated third party in October 2017 in the amount of $ 60,000 76,076 12,149 2.0% 148,225 18,701 166,926 2.0% 166,926 18,917 29,072,500 23,258 343,056 319,798 166,926 183,619 16,693 16,693 20,866,250 16,693 73,032 16,693 56,339 166,926 0.002 ● In November 2017, we issued a promissory note to an unrelated third party in the amount of $ 120,000 20,000 50,000 125,000,000 87,500 37,500 36,000,000 10,000,000 32,200 70,000 14,000 84,000 84,000 ● In November 2017, we issued a promissory note to an unrelated third party in the amount of $ 18,000 3,000 18,000 2,000 (3) At December 31, 2021 and 2020, the balance of $ 3,751,760 1,276,902 283,430 101,448 ● On March 19, 2014, we issued two Convertible Debentures in the amount of up to $ 500,000 1,000,000 15,000 30,000 8% March 19, 2018 3,000 27,000 11,412 1,000,000 38,412 ● In October 2017, we issued a promissory note to an unrelated third party in the amount of $ 60,000 10,000 60,000 ● During January through December 2018, we issued convertible notes payable to the 20 unrelated third parties for a total of $ 618,250 62,950 0.0003 0.001 255,655 62,950 28,421 During February 2019, we issued convertible notes payable of $ 70,000 5,000 0.0005 22,000 38,500 7,550 16,500 1,650 0.001 195,178 123,900 38,500 16,500 Month of Issuance Number of Warrants Fair Value of Warrants Recorded as Debt Discount Month of Expiration December, 2019 44,000,000 $ 7,370 August, 2020 August, 2020 92,100,000 $ 38,500 August, 2022 October, 2020 36,300,000 $ 16,500 October, 2022 During May 2019, we restated two convertible notes payable with additional original issue discount of $ 6,400 During November and December 2019, we issued two convertible promissory notes to the unrelated third party for $ 159,500 14,500 0.0002 0.000275 At December 31, 2019, the principal balance of the notes, net of discount of $ 17,370 736,180 17,370 10,000 During the year ended December 31, 2020, we issued convertible notes payable of $ 555,600 53,600 287,400 268,200 0.0002 0.0008 1,000,000 22,000 700 57,500 7,500 71,875,000 0.002 57,500 50,000 7,500 106,032 65,634 At December 31, 2020, the principal balance of the notes, net of discount of $ 101,448 1,276,902 83,720 During the first quarter of 2021, we issued convertible promissory notes to the unrelated third parties for a total of $ 717,667 93,609 864,225 112,725 539,351 70,350 358,800 46,800 0.0003 0.002 228,563 August 29, 2022 During December 2021, in connection with the issuance of three of the above mentioned convertible notes of $ 172,500 22,500 246,428,571 0.002 150,000 22,500 409,374 During March 2021, the remaining balance of promissory note of $ 30,000 0.01 12% 1,000 7,323 22,677 2,677 During March 2021, in connection with the settlement of the $ 6,000 11,000 11,000,000 6,000 104,500 5,000 98,500 8,500 12,000 2,000,000 4,000 15,200 4,500 11,200 During August 2021, the remaining balance of promissory note of $ 166,926 0.002 183,619 16,693 At the date of this report, $ 1,836,904 308,200 283,430 3,751,760 (4) At December 31, 2021 and 2020, the balance of $ 2,855,709 1,832,439 0 22,344 ● The remaining balance of $ 20,000 120,000 20,000 21,183 17,128 84,768 69,433 ● During May 2017, we issued a Convertible Debenture in the amount of $ 64,000 May 4, 2018 20% 12,629 14,833 12,308 70,418 49,875 ● During February through August 2018, we issued seven convertible promissory notes to an unrelated third party due one year from the execution dates. The principal balance of these Notes on December 31, 2019 was $ 511,319 107,133,333 22,000 10,140 107,817,770 22,000 10,345 509,301 234,417 250,000 1,859,294 1,609,294 Number of Fair Value of Date shares converted Debt 9/21/2020 107,133,333 $ 171,413 10/5/2020 107,817,770 $ 64,691 ● The new note of $ 250,000 8% We have increased the outstanding principal due by 10% and accrued interest at default interest rate of 24% after the note’s maturity date. 286,969 250,000 3,890 521,370 275,000 32,657 946,639 ● During July 2018, we issued a convertible debenture in the amount of $ 50,000 8% We have accrued interest at default interest rate of 24% after the note’s maturity date. The Note holder has the right to convert the note into shares of Common Stock at fifty five percent of the average three lowest trading price of our restricted common stock for the fifteen trading days including the date of receipt of conversion notice. 46,734 50,000 33,490 21,490 202,401 146,232 ● During August 2018, we issued a convertible debenture in the amount of $ 20,000 8% We have accrued interest at default interest rate of 24% after the note’s maturity date. The Note holder has the right to convert the note into shares of Common Stock at fifty five percent of the average three lowest trading price of our restricted common stock for the fifteen trading days including the date of receipt of conversion notice. 17,829 12,923 11,713 79,815 57,524 ● During January 2019, the principal balance of $ 60,000 75,000 15,900 75,900 75,900 20,000 75,900 100,000,000 20,000 140,000 At December 31, 2021 and 2020, the convertible note payable of $ 55,900 156,000 129,832 ● During February 2019, we issued a convertible promissory note to an unrelated third party in the amount up to $ 1,000,000 paid upon tranches. The note is due two years from the execution and funding of the note per tranche. The Noteholder has the right to convert the note into shares of Common Stock at a conversion price of the lower of $ 0.0005 or 50% discount to the average trading price of the three lowest closing stock prices for the twenty days prior to the notice of conversion. The eight total tranches of the Note in the amount of $ 372,374 and $ 20,199 have been funded during 2019 and 2020, respectively. An additional three tranches of the Note for a total of $ 132,000 have been funded, and repayment of $ 40,480 has been made during year ended December 31, 2021. In connection with issuance of the convertible note, the Noteholder agreed to eliminate two outstanding Notes of $ 27,000 and the accrued interest of $ 11,412 that were held by the Noteholder’s defunct entities. In connection with the issuance of the convertible note payable tranches during the year ended December 31, 2021 and 2020, we recorded a day-one derivative loss of $ 2,042,612 and $ 31,205 . During May and June 2019, the Note holder made conversions of a total of 750,000,000 shares of stock satisfying the principal balance of $ 100,000 for a fair value of $ 275,000 . During January 2020 through February 2020, the Note holder received a total of 500,000,000 shares of our restricted common stock in satisfaction the $ 175,000 of the Note with a fair value of $ 425,000 . During February through June 2021, the Note holder received a total of 240,350,000 shares of our restricted common stock in satisfaction the $ 120,175 of the Note with a fair value of $ 2,344,399 (See Note 7). The remaining balance of $ 88,917 is due September 2023. At December 31, 2021 and 2020, the convertible note payable with principal balance of $ 88,917 and $ 117,572 , at fair value, was recorded at $ 355,668 and $ 282,173 . Number of Fair Value of Date shares converted Debt Converted 2/25/2021 137,700,000 $ 1,500,930 3/3/2021 67,380,000 $ 599,682 4/26/2021 27,070,000 $ 192,197 6/1/2021 5,700,000 $ 35,340 6/24/2021 2,500,000 $ 16,250 ● During June 2019, we issued a convertible promissory note to an unrelated third party for $ 240,000 40,000 16,000,000 4,688 0.0005 240,000 22,344 240,000 960,000 576,000 (5) At December 31, 2021 and 2020, the balance of $ 225,000 (6) During May 2020, we entered into a two-year loan agreement with the U. S. Small Business Administration for a Payroll Protection Program (PPP) loan, for $ 64,895 1% 24 During April and June 2020, the Company executed the standard loan documents required for securing a loan from the SBA under its Economic Injury Disaster Loan assistance program (the “EIDL Loan”) considering the impact of the COVID-19 pandemic on the Company’s business. Pursuant to the Loan Authorization and Agreement (the “SBA Loan Agreement”), the principal amount of the EIDL Loan was $ 150,000 3.75% 24 731 5,000 8,906 3,660 At December 31, 2021, the future minimum principal payments for the EIDL loan is as follows: SCHEDULE OF FUTURE MINIMUM PRINCIPAL PAYMENT Years Amount 2022 $ 2,121 2023 3,283 2024 3,408 2025 3,538 2026 3,673 Thereafter 133,877 Total $ 149,900 Less: Long-term portion - SBA notes payable (147,779 ) Current portion $ 2,121 |
STOCKHOLDERS_ DEFICIT
STOCKHOLDERS’ DEFICIT | 12 Months Ended |
Dec. 31, 2021 | |
Equity [Abstract] | |
STOCKHOLDERS’ DEFICIT | 7 . STOCKHOLDERS’ DEFICIT Authorized Shares On November 18, 2021, we obtained written consents from stockholders holding a majority of our outstanding voting stock to approve an amendment of the Company’s articles of incorporation, as amended, to increase the number of authorized shares of common stock from 8,000,000,000 12,000,000,000 Series A Preferred Stock Effective October 30, 2017, pursuant to authority of its Board of Directors, the Company filed a Certificate of Determination to authorize the issuance of 20,000,000 Effective October 30, 2017 the Board of Directors authorized the issuance of 3,000,000 1. The Series A Preferred voted with the Company’s common stock as a single class on all matters or consents for the Company’s common stockholders. Each share of Series A Preferred is entitled to one thousand votes per share. 2. The Series A Preferred was not entitled to dividends unless the Company paid cash dividends or dividends in other property to holders of outstanding shares of common stock, in which event, each outstanding share of the Series A Preferred was entitled to receive dividends of cash or property in an amount or value equal to one thousand multiplied by the amount paid in respect of one share of common stock. Any dividend payable to the Series A Preferred would have the same record and payment date and terms as the dividend payable on the common stock. 3. The Series A Preferred did not have any redemption rights. Effective November 15, 2021, the Board of Directors authorized an exchange of 3,000,000 shares of Series A Preferred Stock held by Mr. Deitsch for an equal number of Series B Preferred Stock. Upon return of 100% of Series A Preferred Stock to the Company, the entire class of Series A Preferred Stock was cancelled and the associated Certificate of Determination was filed with the Secretary of State of California. Series B Preferred Stock Effective March 2021, pursuant to authority of its Board of Directors, the Company filed a Certificate of Determination for its Series B Preferred Stock. The Series B Preferred Stock has a par value of $ 0.001 per shares and consists of 12,000,000 shares. Terms of the Series B Preferred include the following: 1. The Series B Preferred votes with the Company’s common stock as a single class on all matters or consents for the Company’s common stockholders. Each share of Series B Preferred is entitled to one thousand votes per share. 2. The Series B Preferred will not be entitled to dividends unless the Company pays cash dividends or dividends in other property to holders of outstanding shares of common stock, in which event, each outstanding share of the Series B Preferred will be entitled to receive dividends of cash or property in an amount or value equal to one thousand multiplied by the amount paid in respect of one share of common stock. Any dividend payable to the Series B Preferred will have the same record and payment date and terms as the dividend payable on the common stock. 3. Upon any voluntary or involuntary liquidation, dissolution or winding up of the Company, the holders of all shares of Series B Preferred then outstanding shall be entitled to be paid out of the assets of the Company available for distribution to its stockholders an amount in cash equal to $ 0.133 4. The Series B Preferred does not have any redemption rights. During November 2021, the Board of Directors approved resolutions for the issuance of a total of 9,000,000 shares of Series B Preferred stock to Mr. Deitsch to discharge $ 540,000 of his accrued salary. The shares were valued at the accrued payable amount by agreement of the parties. Effective November 15, 2021, the Board of Directors authorized an exchange of 3,000,000 shares of Series A Preferred Stock held by Mr. Deitsch for an equal number of Series B Preferred Stock. Settlement of accrued interest of a related-party Note During October 2021, we issued 12,500,000 shares of common stock to satisfy the $ 10,000 accrued interest of a related-party note of $ 200,000 originated in 2010. The shares were valued at the accrued payable amount by agreement of the parties. Common Stock Issued for Conversion of Convertible Debt During February through June 2021, the Note holder received a total of 240,350,000 120,175 2,344,399 SCHEDULE OF COMMON STOCK ISSUED FOR CONVERSION OF DEBT Number of Fair Value of Date shares converted Debt Converted 2/25/2021 137,700,000 $ 1,500,930 3/3/2021 67,380,000 $ 599,682 4/26/2021 27,070,000 $ 192,197 6/1/2021 5,700,000 $ 35,340 6/24/2021 2,500,000 $ 16,250 During January 2020 through February 2020, the Note holder made conversions of a total of 500,000,000 175,000 Number of Fair Value of Date shares Debt 1/21/2020 250,000,000 $ 150,000 2/18/2020 250,000,000 $ 275,000 During February through August 2018, we issued seven convertible promissory notes to an unrelated third party due one year from the execution dates. The principal balance of these Notes prior to the following conversions was $ 511,319 . During September 2020, the Note holder received a total of 107,133,333 shares of our restricted common stock in satisfaction of the principal balance of $ 22,000 and accrued interest of $ 10,140 . During October 2020, the Note holder received a total of 107,817,770 shares of our restricted common stock in satisfaction of the principal balance of $ 22,000 and accrued interest of $ 10,345 . Number of Fair Value of Date shares converted Debt 9/21/2020 107,133,333 $ 171,413 10/5/2020 107,817,770 $ 64,691 During November 2020, the Note holder assigned $ 20,000 75,900 100,000,000 20,000 140,000 Common Stock Issued for Debt Modification and Penalty During January 2021, we issued a total of 25,000,000 166,926 107,500 During January 2020, we issued a total of 75,000,000 45,000 During March 2020, $ 50,000 120,000 20,000 125,000,000 36,000,000 10,000,000 119,700 During June 2020, we issued 5,000,000 14,400 3,000 During July 2020, we issued a total of 1,000,000 22,000 700 During September 2020, we issued a total of 10,000,000 333,543 6,000 During October 2020, we issued a total of 1,500,000 84,000 900 Common Stock Issued for Settlement of Debt During February 2021, we issued 29,072,500 23,258 166,926 343,056 319,798 During March 2021, in connection with the settlement of a Note of $ 11,000 11,000,000 6,000 104,500 5,000 98,500 During April 2021, in connection with the settlement of the remaining balance of $ 8,500 12,000 2,000,000 4,000 15,200 11,200 During August 2021, in connection with the settlement of $ 16,693 183,619 20,866,250 73,032 56,339 Common Stock Issued for Services During June 2021, the Company signed an agreement with a consultant for services for six months for which the Company is to issue a total of 30,000,000 5,000,000 25,000,000 5,000,000 33,000 25,000,000 100,000 133,000 During July 2021, the Company signed an agreement with a consultant for services for twelve months. The 5,000,000 41,000 20,500 20,500 During April 2019, we signed an agreement with a consultant to provide investor relation services for twelve months. In connection with the agreement, 120,000,000 24,000 15,000,000 6,000 8,500 |
STOCK WARRANTS
STOCK WARRANTS | 12 Months Ended |
Dec. 31, 2021 | |
Share-based Payment Arrangement [Abstract] | |
STOCK WARRANTS | 8. STOCK WARRANTS Common Stock Warrants On March 31, 2017, in connection with the issuance of an $ 80,000 three 6,000,000 0.005 March 30, 2020 On March 3, 2016, in connection with the issuance of a convertible note, we granted five 2,500,000 0.03 0 9 March 3, 2021 During December 2019, the Company granted 44,000,000 0.001 22,000 7,370 During August 2020, convertible promissory notes of $ 38,500 were amended with additional original issuance discount of $ 7,550 due February 2021. These notes were further amended to due August 2022 on January 1, 2022. During October 2020, a convertible promissory note of $ 16,500 was amended to add additional OID of $ 1,650 due October 2022. In connection with the issuance of amended convertible notes, the Company granted the following warrants at an exercise price of $ 0.001 per share. The warrants were valued using the Black-Scholes method and recorded as a debt discount. The Company classified embedded conversion features in the warrants as a derivative liability. The warrants were valued at their fair value of $ 195,178 and $ 123,900 on December 31, 2021 and 2020 (see Note 6). SCHEDULE OF WARRANTS ISSUED Fair Value of Month of Issuance Number of Warrants Month of August, 2020 92,100,000 $ 38,500 August, 2022 October, 2020 36,300,000 $ 16,500 October, 2022 During November and December, 2020, the Company granted the 71,875,000 0.002 57,500 7,500 57,500 106,032 65,634 During December 2021, in connection with the issuance of three of the convertible notes of $ 172,500 22,500 246,428,571 0.002 409,374 A summary of warrants outstanding in conjunction with private placements of common stock were as follows during the years ended December 31, 2021 and 2020: SUMMARY OF WARRANTS OUTSTANDING Number Of Weighted Balance December 31, 2019 52,500,000 $ 0.0028 Exercised - - Issued 200,275,000 0.0014 Expired (50,000,000 ) 0.0015 Balance December 31, 2020 202,775,000 $ 0.0017 Exercised - - Issued 410,403,571 0.0018 Expired (166,475,000 ) 0.0019 Balance December 31, 2021 446,703,571 $ 0.0017 The following table summarizes information about fixed-price warrants outstanding as of December 31, 2021 and 2020 : SUMMARY OF FIXED PRICE WARRANTS OUTSTANDING Exercise Price Weighted Average Number Outstanding Weighted Weighted 2020 $ 0.001 0.03 202,775,000 0.93 years $ 0.0017 2021 $ 0.001 0.002 446,703,571 0.67 $ 0.0017 At December 31, 2021, the aggregate intrinsic value of all warrants outstanding and expected to vest was $ 128,400 0.002 128,400,000 |
INCOME TAXES
INCOME TAXES | 12 Months Ended |
Dec. 31, 2021 | |
Income Tax Disclosure [Abstract] | |
INCOME TAXES | 9. INCOME TAXES The Company’s tax expense differs from the “expected” tax expense for the years ended December 31, 2021 and 2020, are approximately as follows. SCHEDULE OF INCOME TAX EXPENSE December 31, 2021 2020 Computed “expected” tax expense (benefit) - Federal $ (2,750,059 ) (161,529 ) Computed “expected” tax expense (benefit) - State (569,000 ) (33,421 ) Permanent differences and other 2,783,369 (145,667 Change in valuation allowance 535,690 340,617 Provision for income taxes $ - $ - SCHEDULE OF DEFERRED INCOME TAX ASSETS 2021 2020 Net deferred income tax assets: Reserve for prepaid inventory $ 12,166 $ 23,573 Accrued salary 267,058 362,356 Recovery for receivables from officer - (25,979 ) Net operating loss carryforwards 10,345,757 9,729,342 Valuation allowance (10,624,981 ) (10,089,292 ) Net deferred income tax asset $ - $ - Due to the uncertainty of the utilization and recoverability of the loss carry-forwards and other deferred tax assets, we have provided a valuation allowance to fully reserve such assets. The valuation allowances increased by $ 535,690 and $ 340,617 for the years ended December 31, 2021 and 2020, respectively. As of December 31, 2021, the Company has net operating loss of approximately $ 40.8 million as of December 31, 2021, of which $ 6.0 million were incurred after December 31, 2017 that are available to offset future taxable income with no expiration date. The remaining approximately $ 34.8 million of net operating losses expire between 2023 and 2037. The Company’s 2018 through 2021 tax returns are subject to examination by the Internal Revenue Services and various state authorities. |
ACCRUED EXPENSES
ACCRUED EXPENSES | 12 Months Ended |
Dec. 31, 2021 | |
Payables and Accruals [Abstract] | |
ACCRUED EXPENSES | 10. ACCRUED EXPENSES Accrued expenses consisted of the following: SCHEDULE OF ACCRUED EXPENSES December 31, 2021 2020 Accrued consulting fees $ 161,550 $ 166,900 Accrued settlement expenses - 35,000 Accrued payroll taxes 215,543 215,581 Accrued interest 469,040 351,830 Accrued others 5,337 11,121 Total $ 851,470 $ 780,432 |
PREPAID EXPENSES
PREPAID EXPENSES | 12 Months Ended |
Dec. 31, 2021 | |
Prepaid Expenses | |
PREPAID EXPENSES | 11. PREPAID EXPENSES Prepaid expenses and other current assets consist of the following: SCHEDULE OF PREPAID EXPENSES December 31, December 31, Supplier advances for future purchases $ 294,162 $ 246,162 Reserve for supplier advances (294,162 ) (246,162 ) Net supplier advances - - Prepaid professional fees 65,650 10,000 Deferred stock compensation 20,500 - Total $ 86,150 $ 10,000 We performed an evaluation of our inventory and related accounts at December 31, 2021 and 2020, and increased the reserve on supplier advances for future venom purchases by $ 48,000 21,303 294,162 246,162 |
CONVERTIBLE NOTES RECEIVABLE
CONVERTIBLE NOTES RECEIVABLE | 12 Months Ended |
Dec. 31, 2021 | |
Convertible Notes Receivable | |
CONVERTIBLE NOTES RECEIVABLE | 12. CONVERTIBLE NOTES RECEIVABLE During March through November 2021, we purchased five convertible notes from an unrelated third party (the “Third Party”) for a total of $ 286,550 with original issuance discount of $ 26,050 . The notes are convertible into common shares for $ 0.01 per common share and matures in one year from the funding of the Notes. The original issuance discount is amortized over the lives of notes. The debt discount as of December 31, 2021 was $ 13,070 . Amortization for all the convertible notes receivable was $ 12,980 recognized as other income in the statement of operations for the year ended December 31, 2021. $ 26,950 of the Notes expired on March 10, 2022. We are working on restructuring and converting the Notes into common stock of the Third Party. |
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES | 12 Months Ended |
Dec. 31, 2021 | |
Commitments and Contingencies Disclosure [Abstract] | |
COMMITMENTS AND CONTINGENCIES | 13. COMMITMENTS AND CONTINGENCIES Operating Leases In February 2016, we entered into a three-year operating lease for monthly payments of approximately $ 3,200 the lease on a month-to-month basis until May 2020 when it was terminated ReceptoPharm leases a lab and renewed its operating lease agreement for five years beginning August 1, 2017 for monthly payments of approximately $ 6,900 The lease calls for monthly payments of approximately $ 6,500 SCHEDULE OF LEASE COST AND BALANCE SHEET INFORMATION December 31, December 31, 2021 2020 Lease cost Operating lease cost $ 80,396 $ 89,021 Short-term lease cost - 18,698 Total lease cost $ 80,396 $ 107,719 Balance sheet information Operating ROU Assets $ 93,811 $ 144,010 Operating lease obligations, current portion 77,673 82,873 Operating lease obligations, non-current portion - 60,447 Total operating lease obligations $ 77,673 $ 143,320 Weighted average remaining lease term (in years) – operating leases 1 1.67 Weighted average discount rate-operating leases 8 % 8 % Supplemental cash flow information related to leases were as follows, for the years ended December 31, 2021 and 2020: Cash paid for amounts included in the measurement of operating lease liabilities $ 95,846 $ 98,780 Future minimum payments under the lease agreement are as follows: SCHEDULE OF OPERATING LEASE LIABILITY MATURITY TABLE December 31, Total 2022 $ 81,080 Total future lease payments $ 81,080 Less imputed interest 3,407 Total $ 77,673 Consulting Agreements During July 2015, we signed an agreement with a company to provide for consulting services for five years 500,000 8 50,000 0.18 142,500 During October 2015, the Company signed an agreement with a consultant for consulting services for a year. In connection with the agreement, 2,500,000 3,000 31,750 1,000,000 19,150 1,500,000 Litigation Paul Reid et al. v. Nutra Pharma Corp. et al. On August 26, 2016, certain of former ReceptoPharm employees and a former ReceptoPharm consultant filed a lawsuit in the 17th Judicial Circuit in and for Broward County, Florida (Case No. CACE16–015834) against Nutra Pharma and ReceptoPharm to recover $ 315,000 On June 24, 2021, the parties entered into a confidential settlement agreement of the lawsuit. Nutra Pharma has fully performed under the settlement and considers the case fully resolved. Get Credit Healthy, Inc. v. Nutra Pharma Corp. and Rik Deitsch, Case No. CACE 18-017055 On August 1, 2018, Get Credit Healthy, Inc. filed a lawsuit against the Company and Rik Deitsch (collectively the “Defendants”) in the 17th Judicial Circuit Court in and for Broward County, Florida (Case No. CACE 18-017055) to recover $ 100,000 101,818 21,023 104,000 CSA 8411, LLC v. Nutra Pharma Corp., Case No. CACE 18-023150 On October 12, 2018, CSA 8411, LLC filed a lawsuit against the Company in the 17th Judicial Circuit Court in and for Broward County, Florida (Case No. CACE 18-023150) to recover $ 100,000 91,156 51,856 Defendant also filed affirmative claims against the Plaintiff, its owner Dan Oran and several related entities. The case has not been set for trial as of this date. Securities and Exchange Commission v. Nutra Pharma Corporation, Erik Deitsch, and Sean Peter McManus On September 28, 2018, the United States Securities and Exchange Commission (the “SEC”) filed a lawsuit in the United States District Court for the Eastern District of New York (Case No. 2:18-cv-05459) against the Company, Mr. Deitsch, and Mr. McManus. The lawsuit alleges that, from July 2013 through June 2018, the Company and the other defendants’ defrauded investors by making materially false and misleading statements about the Company and violated anti-fraud and other securities laws. The violations alleged against the Company by the SEC include: (a) raising over $920,000 in at least two private placement offerings for which the Company failed to file required registration statements with the SEC; (b) issuing a series of materially false or misleading press releases; (c) making false statements in at least one Form 10-Q; and (d) failing to make required public filings with the SEC to disclose the Company’s issuance of millions of shares of stock. The lawsuit makes additional allegations against Mr. McManus and Mr. Deitsch, including that Mr. McManus acted as a broker without SEC registration and defrauded at least one investor by making false statements about the Company, that Mr. Deitsch engaged in manipulative trades of the Company’s stock by offering to pay more for shares he was purchasing than the amount the seller was willing to take, and that Mr. Deitsch failed to make required public filings with the SEC. The lawsuit seeks both injunctive and monetary relief On May 29, 2019 (following each of the defendants filing motions to dismiss), the SEC filed a First Amended Complaint which generally alleged the same conduct as its original Complaint, but accounted for certain guidance provided by the United States Supreme Court in a case that had been recently decided. Each of the defendants then moved to dismiss the SEC’s First Amended Complaint. On March 31, 2020, the Court entered an Order granting in part and denying in part the various motions to dismiss. Following that Order, the SEC filed a Second Amended Complaint (the operative pleading) and the defendants have filed their answers which generally deny liability. At this time, discovery is closed and the SEC has indicated an intent to file a summary judgment motion regarding certain non-fraud claims asserted in its Second Amended Complaint. The defendants have opposed the SEC’s request to file such motion(s). The Court conducted a hearing on February 23, 2021 and set an initial briefing schedule for the SEC’s Motion for Partial Summary Judgment wherein the Plaintiffs’ Motion for Partial Summary Judgment was due on April 5, 2021, the Defendants’ Consolidated (i.e., collectively, Nutra Pharma Corporation, Erik “Rik” Deitsch, and Sean McManus) Response Brief to the SEC’s Motion was due May 3, 2021, and the Plaintiffs’ Reply Brief was due on May 19, 2021. On March 23, 2021, the Plaintiff filed a Motion for Extension of Time to file the Motion for Partial Summary Judgment. On April 9, 2021, the Plaintiff filed a Motion for Partial Summary Judgment, Defendants’ filed a Memorandum of Law in Opposition to Plaintiff’s Motion on May 7, 2021, and Plaintiff filed its Reply brief on May 21, 2021. At this time, the Court has not ruled on the pending Motion. The Company disputes the allegations in this lawsuit and continues to vigorously defend against the SEC’s claims. Mr. Deitsch and Mr. McManus have similarly defended the lawsuit since its filing and each contest liability. The Company does not believe that it engaged in any fraudulent activity or made any material misrepresentations concerning the Company and/or its products. |
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS | 12 Months Ended |
Dec. 31, 2021 | |
Subsequent Events [Abstract] | |
SUBSEQUENT EVENTS | 14. SUBSEQUENT EVENTS Convertible Notes Payable Pursuant to the Note agreement in the amount up to $ 1,000,000 signed in February 2019, As of December 31, 2021, the remaining balance of $ 88,917 is due September 2023. During February 2022, the Note holder made a conversion of 12,000,000 shares of stock satisfying the principal balance of $ 6,000 for a fair value of $ 36,000 . During the first quarter of 2022, we issued convertible promissory notes to the unrelated third parties for a total of $ 225,000 75,000 0.0005 0.0008 Restatement of Promissory Notes During February 2022, the restated Note of $ 183,619 16,693 20,866,250 16,693 54,252 37,559 183,619 16,693 Promissory Notes During January 2022, the Company received a loan for a total of $ 199,000 63.76 4,975 |
BASIS OF PRESENTATION AND SUM_2
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) | 12 Months Ended |
Dec. 31, 2021 | |
Accounting Policies [Abstract] | |
Organization | Organization Nutra Pharma Corp. (“Nutra Pharma”), is a holding company that owns intellectual property and operates in the biotechnology industry. Nutra Pharma was incorporated under the laws of the state of California on February 1, 2000, under the original name of Exotic-Bird.com. Through its wholly-owned subsidiary, ReceptoPharm, Inc. (“ReceptoPharm”), Nutra Pharma conducts drug discovery research and development activities. In October 2009, Nutra Pharma launched its first consumer product called Cobroxin ® ® ® Luxury Feet, an over-the-counter pain reliever and anti-inflammatory product that is designed for women who experience pain or discomfort due to high heels and stilettos. In October of 2021 we began manufacturing a zeolite detoxifier called Cell Defender for a third party distributor. |
Basis of Presentation and Consolidation | Basis of Presentation and Consolidation The accompanying Consolidated Financial Statements include the results of Nutra Pharma and its wholly-owned subsidiaries Designer Diagnostics Inc. and ReceptoPharm (collectively “the Company”, “us”, “we” or “our”). We operate as one reportable segment. Designer Diagnostics Inc. has been inactive since June 2011. All intercompany transactions and balances have been eliminated in consolidation. |
Liquidity and Going Concern | Liquidity and Going Concern Our Consolidated Financial Statements are presented on a going concern basis, which contemplate the realization of assets and satisfaction of liabilities in the normal course of business. We have experienced recurring, significant losses from operations, and have an accumulated deficit of $ 81,728,989 20,606,665 20,877,650 There is substantial doubt regarding our ability to continue as a going concern which is contingent upon our ability to secure additional financing, increase ownership equity and attain profitable operations. In addition, our ability to continue as a going concern must be considered in light of the problems, expenses and complications frequently encountered in established markets and the competitive environment in which we operate. We do not have sufficient cash to sustain our operations for a period of twelve months from the issuance date of this report and will require additional financing in order to execute our operating plan and continue as a going concern. Since our sales are not currently adequate to fund our operations, we continue to rely principally on debt and equity funding; however, proceeds from such funding have not been sufficient to execute our business plan. Our plan is to attempt to secure adequate funding until sales of our pain products are adequate to fund our operations. We cannot predict whether additional financing will be available, and/or whether any such funding will be in the form of equity, debt, or another form. In the event that these financing sources do not materialize, or if we are unsuccessful in increasing our revenues and profits, we will be unable to implement our current plans for expansion, repay our obligations as they become due and continue as a going concern. The accompanying Consolidated Financial Statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern. |
Impact of COVID-19 on our Operations | Impact of COVID-19 on our Operations The ramifications of the outbreak of the novel strain of COVID-19, reported to have started in December 2019 and spread globally, are filled with uncertainty and changing quickly. Our operations have continued during the COVID-19 pandemic and we have not had significant disruption. Beginning in June 2020, the Company experienced a delay in retail rollout as a downstream implication of the slowing economy. We also closed our Coral Springs office in effort to save money. During May 2020, we received approval from the Small Business Administration (“SBA”) to fund our request for a PPP loan for $ 64,895 150,000 The Company is operating in a rapidly changing environment so the extent to which COVID-19 impacts its business, operations and financial results from this point forward will depend on numerous evolving factors that the Company cannot accurately predict. Those factors include the following: the duration and scope of the pandemic; governmental, business and individuals’ actions that have been and continue to be taken in response to the pandemic; and the distribution of testing and a vaccine. |
Use of Estimates | Use of Estimates The accompanying Consolidated Financial Statements are prepared in accordance with accounting principles generally accepted in the United States of America which require management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense. Significant estimates include our ability to continue as going concern, the recoverability of inventories and long-lived assets, the recoverability of amounts due from officer, the valuation of stock-based compensation and certain debt and derivative liabilities, recognition of loss contingencies and deferred tax valuation allowances. Actual results could differ from those estimates. Changes in facts and circumstances may result in revised estimates, which would be recorded in the period in which they become known. |
Revenue from Contracts with Customers | Revenue from Contracts with Customers The Company accounts for revenue from contracts with customers in accordance with Financial Accounting Standard Board (“FASB”) Accounting Standard Codification (“ASC”) Topic 606, Revenue from Contracts with Customers Our revenues are primarily derived from customer orders for the purchase of our products. We recognize revenues as performance obligations are fulfilled upon shipment of products. We record revenues net of promotions and discounts. For certain product sales to a distributor, we record revenue including a portion of the cash proceeds that is remitted back to the distributor. |
Accounting for Shipping and Handling Costs | Accounting for Shipping and Handling Costs We account for shipping and handling as fulfilment activities and record amounts billed to customers as revenue and the related shipping and handling costs as cost of sales. |
Accounts Receivable and Allowance for Doubtful Accounts | Accounts Receivable and Allowance for Doubtful Accounts We grant credit without collateral to our customers based on our evaluation of a particular customer’s credit worthiness. Accounts receivable are due 30 days after the issuance of the invoice. In addition, allowances for doubtful accounts are maintained for potential credit losses based on the age of the accounts receivable and the results of periodic credit evaluations of our customers’ financial condition. Accounts receivable are written off after collection efforts have been deemed to be unsuccessful. Accounts written off as uncollectible are deducted from the allowance for doubtful accounts, while subsequent recoveries are netted against the provision for doubtful accounts expense. We generally do not charge interest on accounts receivable. We use third party payment processors and are required to maintain reserve balances, which are included in accounts receivable. Accounts receivable are stated at estimated net realizable value. Accounts receivable are comprised of balances due from customers net of estimated allowances for uncollectible accounts. No |
Inventories | Inventories Inventories, which are stated at the lower of average cost or net realizable value, consist of packaging materials, finished products, and raw venom that is utilized to make the API (active pharmaceutical ingredient). The raw unprocessed venom has an indefinite life for use. Commencing on October 1, 2019, we classify inventory as short-term or long-term inventory based on timing of when it is expected to be consumed. The Company regularly reviews inventory quantities on hand. If necessary, it records a net realizable value adjustment for excess and obsolete inventory based primarily on its estimates of product demand and production requirements. Write-downs are charged to cost of goods sold. We performed an evaluation of our inventory and related accounts at December 31, 2021 and 2020, and increased the reserve on supplier advances for future venom purchases included in prepaid expenses and other current assets by $ 48,000 21,303 294,162 246,162 |
Financial Instruments and Concentration of Credit Risk | Financial Instruments and Concentration of Credit Risk Our financial instruments include cash, accounts receivable, accounts payable, accrued expenses, loans payable, due to officers and derivative financial instruments. Other than certain warrant and convertible instruments (derivative financial instruments) and liabilities to related parties (for which it was impracticable to estimate fair value due to uncertainty as to when they will be satisfied and a lack of similar type transactions in the marketplace), we believe the carrying values of our financial instruments approximate their fair values because they are short term in nature or payable on demand. Our derivative financial instruments are carried at a measured fair value. Balances in various cash accounts may at times exceed federally insured limits. We have not experienced any losses in such accounts. We do not hold or issue financial instruments for trading purposes. In addition, for the year ended December 31, 2021, there was one customer that accounted for 21 37 100 |
Operating Lease Right-of-Use Asset and Liability | Operating Lease Right-of-Use Asset and Liability The Company accounts for leases in accordance with Accounting Standards Update (“ASU”) 2016-02, Leases In accordance with ASC Topic 842, at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present and the classification of the lease including whether the contract involves the use of a distinct identified asset, whether we obtain the right to substantially all the economic benefit from the use of the asset, and whether we have the right to direct the use of the asset. Leases with a term greater than one year are recognized on the balance sheet as ROU assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less under practical expedient in paragraph ASC 842-20-25-2. Lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected lease term. The implicit rate within our operating leases are generally not determinable and, therefore, the Company uses the incremental borrowing rate at the lease commencement date to determine the present value of lease payments. The determination of the Company’s incremental borrowing rate requires judgment. The Company determines the incremental borrowing rate for each lease using our estimated borrowing rate. |
Derivative Financial Instruments | Derivative Financial Instruments Management evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported as charges or credits to income. For option-based simple derivative financial instruments, the Company uses the Black-Scholes option-pricing model to value the derivative instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date. We do not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. |
Convertible Debt | Convertible Debt For convertible debt that does not contain an embedded derivative that requires bifurcation, the conversion feature is evaluated to determine if the rate of conversion is below market value and should be categorized as a beneficial conversion feature (“BCF”). A BCF related to debt is recorded by the Company as a debt discount and with the offset recorded to equity. The related convertible debt is recorded net of the discount for the BCF. The discount is amortized as additional interest expense over the term of the debt with the resulting debt discount being accreted over the term of the note. |
The Fair Value Measurement Option | The Fair Value Measurement Option We have elected the fair value measurement option for convertible debt with embedded derivatives that require bifurcation, and record the entire hybrid financing instrument at fair value under the guidance of ASC Topic 815, Derivatives and Hedging |
Derivative Accounting for Convertible Debt and Options and Warrants | Derivative Accounting for Convertible Debt and Options and Warrants The Company evaluated the terms and conditions of the convertible debt under the guidance of ASC 815, Derivatives and Hedging Embedded Derivatives |
Property and Equipment | Property and Equipment Property and equipment is recorded at cost. Expenditures for major improvements and additions are added to property and equipment, while replacements, maintenance and repairs which do not extend the useful lives are expensed. Depreciation is computed using the straight-line method over the estimated useful lives of the assets of 3 7 |
Long-Lived Assets | Long-Lived Assets The carrying value of long-lived assets is reviewed annually and on a regular basis for the existence of facts and circumstances that may suggest impairment. If indicators of impairment are present, we determine whether the sum of the estimated undiscounted future cash flows attributable to the long-lived asset in question is less than its carrying amount. If less, we measure the amount of the impairment based on the amount that the carrying value of the impaired asset exceeds the discounted cash flows expected to result from the use and eventual disposal of the impaired assets. |
Income Taxes | Income Taxes We compute income taxes in accordance with FASB ASC Topic 740, Income Taxes On an annual basis, we evaluate tax positions that have been taken or are expected to be taken in our tax returns to determine if they are more than likely to be sustained if the taxing authority examines the respective position. At December 31, 2021 and 2020, we do not believe we have a need to record any liabilities for uncertain tax positions or provisions for interest or penalties related to such positions. |
Stock-Based Compensation | Stock-Based Compensation We account for stock-based compensation in accordance with FASB ASC Topic 718, Stock Compensation |
Net Loss Per Share | Net Loss Per Share Net loss per share is calculated in accordance with ASC Topic 260, Earnings per Share SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF NET LOSS PER SHARE 31-Dec-21 31-Dec-20 Options and warrants 446,703,571 202,775,000 Convertible notes payable at fair value 1,427,853,386 1,515,706,865 Convertible notes payable 4,913,379,125 2,814,694,508 Total 6,787,936,082 4,533,176,373 |
Recent Accounting Pronouncements | Recent Accounting Pronouncements In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326) In August 2020, the FASB issued ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity In May 2021, the FASB issued ASU No. 2021-04, Earnings Per Share (Topic 260), Debt – Modifications and Extinguishments (Subtopic 470-50), Compensation – Stock Compensation (Topic 718), and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modification or Exchanges of Freestanding Equity-Classified Written Call Options (“ASU 2021-04”), which will clarify and reduce diversity in practice. Specifically, the new standard includes a recognition model comprising four categories of transactions and corresponding accounting treatment for each category. The category that would apply to a modification or an exchange of an equity-classified warrant would depend on the substance of the modification transaction (e.g. a financing transaction to raise equity versus one to raise debt). This recognition model is premised on the idea that the accounting for the transaction should not differ from what it would have been had the issuer of the warrants paid cash instead of modifying the warrants. ASU 2021-04 will be effective for fiscal years beginning after December 15, 2021 and interim periods within those fiscal years. This ASU will be applied prospectively to modifications or exchanges occurring on or after the effective date of the ASU. The Company is currently evaluating the impact this new guidance will have on its consolidated financial statements. All other newly issued accounting pronouncements but not yet effective have been deemed either immaterial or not applicable. |
BASIS OF PRESENTATION AND SUM_3
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Accounting Policies [Abstract] | |
SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF NET LOSS PER SHARE | SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF NET LOSS PER SHARE 31-Dec-21 31-Dec-20 Options and warrants 446,703,571 202,775,000 Convertible notes payable at fair value 1,427,853,386 1,515,706,865 Convertible notes payable 4,913,379,125 2,814,694,508 Total 6,787,936,082 4,533,176,373 |
FAIR VALUE MEASUREMENTS (Tables
FAIR VALUE MEASUREMENTS (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Short-term Debt [Line Items] | |
SUMMARY OF FINANCIAL INSTRUMENTS MEASURED AT FAIR VALUE | The following table summarizes our financial instruments measured at fair value at December 31, 2021 and December 31, 2020: SUMMARY OF FINANCIAL INSTRUMENTS MEASURED AT FAIR VALUE Fair Value Measurements at December 31, 2021 Liabilities: Total Level 1 Level 2 Level 3 Warrant liability $ 710,585 $ - $ - $ 710,585 Derivative liabilities $ 9,826,759 $ - $ 9,826,759 $ - Convertible notes at fair value $ 2,855,709 $ - $ - $ 2,855,709 Fair Value Measurements at December 31, 2020 Liabilities: Total Level 1 Level 2 Level 3 Warrant liability $ 189,543 $ - $ - $ 189,543 Derivative liabilities $ 3,377,633 $ - $ 3,377,633 $ - Convertible notes at fair value $ 1,832,439 $ - $ - $ 1,832,439 |
SUMMARY OF CHANGES IN FAIR VALUE MEASUREMENTS USING SIGNIFICANT UNOBSERVABLE INPUTS | The following table shows the changes in fair value measurements for the warrant liability using significant unobservable inputs (Level 3) during the years ended December 31, 2021 and 2020: SUMMARY OF CHANGES IN FAIR VALUE MEASUREMENTS USING SIGNIFICANT UNOBSERVABLE INPUTS Description 2021 2020 Beginning balance $ 189,543 $ 1,411 Purchases, issuances, and settlements 590,885 143,369 Total loss (gain) included in earnings (1) (69,843 ) 44,763 Total loss (gain) included in earnings (69,843 ) 44,763 Ending balance $ 710,885 $ 189,543 (1) The loss (gain) related to the revaluation of our warrant liability is included in “Change in fair value of convertible notes and derivatives” in the accompanying consolidated statement of operations. |
SUMMARY OF ASSUMPTIONS AND THE SIGNIFICANT TERMS | The following table summarizes assumptions and the significant terms of the convertible notes for which the entire hybrid instrument is recorded at fair value at December 31, 2021 and 2020: SUMMARY OF ASSUMPTIONS AND THE SIGNIFICANT TERMS Conversion Price - Lower of Fixed Debenture Face Interest Default Discount Anti-Dilution % of stock price for look-back period Look-back 2021 $ 762,446 8 10 20 24 N/A $ 0.00050 0.00097 50 60 3 25 2020 $ 766,101 8 10 20 24 N/A $ 0.00050 0.00064 50 60 3 25 |
Convertible Notes Payable [Member] | |
Short-term Debt [Line Items] | |
SUMMARY OF CHANGES IN FAIR VALUE MEASUREMENTS USING SIGNIFICANT UNOBSERVABLE INPUTS | SUMMARY OF CHANGES IN FAIR VALUE MEASUREMENTS USING SIGNIFICANT UNOBSERVABLE INPUTS Description 2021 2020 Beginning balance $ 1,832,439 $ 5,814,047 Purchases and issuances 132,000 25,981 Day one loss on value of hybrid instrument (1) 2,042,612 318,174 Day one loss on value of hybrid instrument 2,042,612 318,174 Loss (gain) from change in fair value (1) 1,233,538 (1,931,927 Loss (gain) from change in fair value 1,233,538 (1,931,927 Gain on settlement - (1,609,294 Debt discount - 22,344 Repayments in cash (40,480 ) (5,782 ) Conversion to common stock (2,344,399 ) (801,104 ) Ending balance $ 2,855,709 $ 1,832,439 (1) The (gains) losses related to the valuation of the convertible notes are included in “Change in fair value of convertible notes and derivatives” in the accompanying consolidated statement of operations. |
INVENTORIES (Tables)
INVENTORIES (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Inventory Disclosure [Abstract] | |
SCHEDULE OF INVENTORIES | Inventories are valued at the lower of cost or net realizable value on an average cost basis. At December 31, 2021 and 2020, inventories were as follows: SCHEDULE OF INVENTORIES December 31, 2021 December 31, 2020 Raw Materials $ 126,349 $ 78,880 Finished Goods 3,820 5,271 Total Inventories 130,169 84,151 Less: Long-term inventory (98,880 ) (78,880 ) Current portion $ 31,289 $ 5,271 |
PROPERTY AND EQUIPMENT (Tables)
PROPERTY AND EQUIPMENT (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Property, Plant and Equipment [Abstract] | |
SCHEDULE OF PROPERTY AND EQUIPMENT | Property and equipment consists of the following at December 31, 2021 and 2020: SCHEDULE OF PROPERTY AND EQUIPMENT December 31, December 31, Computer equipment $ 25,120 $ 25,120 Furniture and fixtures 34,757 34,757 Lab equipment 104,564 65,521 Telephone equipment 12,421 12,421 Office equipment – other 16,856 16,856 Leasehold improvements 73,168 73,168 Total 266,886 227,843 Less: Accumulated depreciation (222,185 ) (213,101 ) Property and equipment, net $ 44,701 $ 14,742 |
DEBTS (Tables)
DEBTS (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Debt Disclosure [Abstract] | |
SCHEDULE OF DEBT | Debts consist of the following at December 31, 2021 and 2020: SCHEDULE OF DEBT December 31, 2021 December 31, 2020 Notes payable – Unrelated third parties (Net of discount of $ 0 1,500 $ 1,135,257 $ 1,346,057 Convertible notes payable – Unrelated third parties (Net of discount of $ 283,429 101,448 3,751,760 1,276,902 Convertible notes payable, at fair value (4) 2,855,709 1,832,439 Other advances from an unrelated third party (5) 225,000 225,000 SBA notes payable(6) 149,900 214,795 Ending balances 8,117,626 4,895,193 Less: Long-term portion-Convertible Notes payable-Unrelated third parties (369,401 ) (48,477 ) Less: Long-term portion- SBA notes payable (147,779 ) (204,070 ) Current portion $ 7,600,446 $ 4,642,646 |
SCHEDULE OF FUTURE MINIMUM PRINCIPAL PAYMENT | SCHEDULE OF FUTURE MINIMUM PRINCIPAL PAYMENT Years Amount 2022 $ 2,121 2023 3,283 2024 3,408 2025 3,538 2026 3,673 Thereafter 133,877 Total $ 149,900 Less: Long-term portion - SBA notes payable (147,779 ) Current portion $ 2,121 |
STOCKHOLDERS_ DEFICIT (Tables)
STOCKHOLDERS’ DEFICIT (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Equity [Abstract] | |
SCHEDULE OF COMMON STOCK ISSUED FOR CONVERSION OF DEBT | SCHEDULE OF COMMON STOCK ISSUED FOR CONVERSION OF DEBT Number of Fair Value of Date shares converted Debt Converted 2/25/2021 137,700,000 $ 1,500,930 3/3/2021 67,380,000 $ 599,682 4/26/2021 27,070,000 $ 192,197 6/1/2021 5,700,000 $ 35,340 6/24/2021 2,500,000 $ 16,250 Number of Fair Value of Date shares Debt 1/21/2020 250,000,000 $ 150,000 2/18/2020 250,000,000 $ 275,000 Number of Fair Value of Date shares converted Debt 9/21/2020 107,133,333 $ 171,413 10/5/2020 107,817,770 $ 64,691 |
STOCK WARRANTS (Tables)
STOCK WARRANTS (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Share-based Payment Arrangement [Abstract] | |
SCHEDULE OF WARRANTS ISSUED | SCHEDULE OF WARRANTS ISSUED Fair Value of Month of Issuance Number of Warrants Month of August, 2020 92,100,000 $ 38,500 August, 2022 October, 2020 36,300,000 $ 16,500 October, 2022 |
SUMMARY OF WARRANTS OUTSTANDING | A summary of warrants outstanding in conjunction with private placements of common stock were as follows during the years ended December 31, 2021 and 2020: SUMMARY OF WARRANTS OUTSTANDING Number Of Weighted Balance December 31, 2019 52,500,000 $ 0.0028 Exercised - - Issued 200,275,000 0.0014 Expired (50,000,000 ) 0.0015 Balance December 31, 2020 202,775,000 $ 0.0017 Exercised - - Issued 410,403,571 0.0018 Expired (166,475,000 ) 0.0019 Balance December 31, 2021 446,703,571 $ 0.0017 |
SUMMARY OF FIXED PRICE WARRANTS OUTSTANDING | The following table summarizes information about fixed-price warrants outstanding as of December 31, 2021 and 2020 : SUMMARY OF FIXED PRICE WARRANTS OUTSTANDING Exercise Price Weighted Average Number Outstanding Weighted Weighted 2020 $ 0.001 0.03 202,775,000 0.93 years $ 0.0017 2021 $ 0.001 0.002 446,703,571 0.67 $ 0.0017 |
INCOME TAXES (Tables)
INCOME TAXES (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Income Tax Disclosure [Abstract] | |
SCHEDULE OF INCOME TAX EXPENSE | The Company’s tax expense differs from the “expected” tax expense for the years ended December 31, 2021 and 2020, are approximately as follows. SCHEDULE OF INCOME TAX EXPENSE December 31, 2021 2020 Computed “expected” tax expense (benefit) - Federal $ (2,750,059 ) (161,529 ) Computed “expected” tax expense (benefit) - State (569,000 ) (33,421 ) Permanent differences and other 2,783,369 (145,667 Change in valuation allowance 535,690 340,617 Provision for income taxes $ - $ - |
SCHEDULE OF INCOME TAX EXPENSE | SCHEDULE OF INCOME TAX EXPENSE December 31, 2021 2020 Computed “expected” tax expense (benefit) - Federal $ (2,750,059 ) (161,529 ) Computed “expected” tax expense (benefit) - State (569,000 ) (33,421 ) Permanent differences and other 2,783,369 (145,667 Change in valuation allowance 535,690 340,617 Provision for income taxes $ - $ - |
SCHEDULE OF DEFERRED INCOME TAX ASSETS | SCHEDULE OF DEFERRED INCOME TAX ASSETS 2021 2020 Net deferred income tax assets: Reserve for prepaid inventory $ 12,166 $ 23,573 Accrued salary 267,058 362,356 Recovery for receivables from officer - (25,979 ) Net operating loss carryforwards 10,345,757 9,729,342 Valuation allowance (10,624,981 ) (10,089,292 ) Net deferred income tax asset $ - $ - |
ACCRUED EXPENSES (Tables)
ACCRUED EXPENSES (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Payables and Accruals [Abstract] | |
SCHEDULE OF ACCRUED EXPENSES | Accrued expenses consisted of the following: SCHEDULE OF ACCRUED EXPENSES December 31, 2021 2020 Accrued consulting fees $ 161,550 $ 166,900 Accrued settlement expenses - 35,000 Accrued payroll taxes 215,543 215,581 Accrued interest 469,040 351,830 Accrued others 5,337 11,121 Total $ 851,470 $ 780,432 |
PREPAID EXPENSES (Tables)
PREPAID EXPENSES (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Prepaid Expenses | |
SCHEDULE OF PREPAID EXPENSES | Prepaid expenses and other current assets consist of the following: SCHEDULE OF PREPAID EXPENSES December 31, December 31, Supplier advances for future purchases $ 294,162 $ 246,162 Reserve for supplier advances (294,162 ) (246,162 ) Net supplier advances - - Prepaid professional fees 65,650 10,000 Deferred stock compensation 20,500 - Total $ 86,150 $ 10,000 |
COMMITMENTS AND CONTINGENCIES (
COMMITMENTS AND CONTINGENCIES (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Commitments and Contingencies Disclosure [Abstract] | |
SCHEDULE OF OPERATING LEASE LIABILITY MATURITY TABLE | SCHEDULE OF LEASE COST AND BALANCE SHEET INFORMATION December 31, December 31, 2021 2020 Lease cost Operating lease cost $ 80,396 $ 89,021 Short-term lease cost - 18,698 Total lease cost $ 80,396 $ 107,719 Balance sheet information Operating ROU Assets $ 93,811 $ 144,010 Operating lease obligations, current portion 77,673 82,873 Operating lease obligations, non-current portion - 60,447 Total operating lease obligations $ 77,673 $ 143,320 Weighted average remaining lease term (in years) – operating leases 1 1.67 Weighted average discount rate-operating leases 8 % 8 % Supplemental cash flow information related to leases were as follows, for the years ended December 31, 2021 and 2020: Cash paid for amounts included in the measurement of operating lease liabilities $ 95,846 $ 98,780 Future minimum payments under the lease agreement are as follows: SCHEDULE OF OPERATING LEASE LIABILITY MATURITY TABLE December 31, Total 2022 $ 81,080 Total future lease payments $ 81,080 Less imputed interest 3,407 Total $ 77,673 |
SCHEDULE OF OPERATING LEASE LIABILITY MATURITY TABLE | Future minimum payments under the lease agreement are as follows: SCHEDULE OF OPERATING LEASE LIABILITY MATURITY TABLE December 31, Total 2022 $ 81,080 Total future lease payments $ 81,080 Less imputed interest 3,407 Total $ 77,673 |
SCHEDULE OF ANTIDILUTIVE SECURI
SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF NET LOSS PER SHARE (Details) - shares | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Antidilutive securities excluded from computation of earnings per share | 6,787,936,082 | 4,533,176,373 |
Option and Warrants [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Antidilutive securities excluded from computation of earnings per share | 446,703,571 | 202,775,000 |
Convertible Notes Payable Fair Value [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Antidilutive securities excluded from computation of earnings per share | 1,427,853,386 | 1,515,706,865 |
Convertible Debt Securities [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Antidilutive securities excluded from computation of earnings per share | 4,913,379,125 | 2,814,694,508 |
BASIS OF PRESENTATION AND SUM_4
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($) | 1 Months Ended | 12 Months Ended | |||
May 31, 2020 | Apr. 30, 2020 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Product Information [Line Items] | |||||
Retained earnings | $ 81,728,989 | $ 68,633,468 | |||
Working capital deficit | 20,606,665 | ||||
Stockholders' equity | 20,877,650 | 11,493,815 | $ 11,701,035 | ||
Allowance for doubtful account | 0 | 0 | |||
Change in reserve for supplier advances for purchases | 48,000 | 21,303 | |||
Inventory valuation allowance | $ 294,162 | $ 246,162 | |||
Minimum [Member] | |||||
Product Information [Line Items] | |||||
Property and equipment estimated useful lives | 3 years | ||||
Maximum [Member] | |||||
Product Information [Line Items] | |||||
Property and equipment estimated useful lives | 7 years | ||||
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | One Customer [Member] | |||||
Product Information [Line Items] | |||||
Concentration risk, percentage | 21.00% | 37.00% | |||
Accounts Receivable [Member] | Customer Concentration Risk [Member] | One Customer [Member] | |||||
Product Information [Line Items] | |||||
Concentration risk, percentage | 100.00% | 100.00% | |||
SBA Loan Agreement [Member] | |||||
Product Information [Line Items] | |||||
Proceeds form loan | $ 64,895 | $ 150,000 |
SUMMARY OF FINANCIAL INSTRUMENT
SUMMARY OF FINANCIAL INSTRUMENTS MEASURED AT FAIR VALUE (Details) - USD ($) | Dec. 31, 2021 | Dec. 31, 2020 |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Warrant liability | $ 710,585 | $ 189,543 |
Derivative liabilities | 9,826,759 | 3,377,633 |
Convertible notes at fair value | 2,855,709 | 1,832,439 |
Fair Value, Inputs, Level 1 [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Warrant liability | ||
Derivative liabilities | ||
Convertible notes at fair value | ||
Fair Value, Inputs, Level 2 [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Warrant liability | ||
Derivative liabilities | 9,826,759 | 3,377,633 |
Convertible notes at fair value | ||
Fair Value, Inputs, Level 3 [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Warrant liability | 710,585 | 189,543 |
Derivative liabilities | ||
Convertible notes at fair value | $ 2,855,709 | $ 1,832,439 |
SUMMARY OF CHANGES IN FAIR VALU
SUMMARY OF CHANGES IN FAIR VALUE MEASUREMENTS USING SIGNIFICANT UNOBSERVABLE INPUTS (Details) - USD ($) | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | ||
Convertible Notes Payable [Member] | |||
Purchases and issuances | $ 132,000 | $ 25,981 | |
Beginning balance | 1,832,439 | 5,814,047 | |
Day one loss on value of hybrid instrument | [1] | 2,042,612 | 318,174 |
Loss (gain) from change in fair value | [1] | 1,233,538 | (1,931,927) |
Gain on settlement | (1,609,294) | ||
Debt discount | 22,344 | ||
Repayments in cash | (40,480) | (5,782) | |
Conversion to common stock | (2,344,399) | (801,104) | |
Ending balance | 2,855,709 | 1,832,439 | |
Warrant [Member] | |||
Beginning balance | 189,543 | 1,411 | |
Purchases and issuances | 590,885 | 143,369 | |
Total loss (gain) included in earnings | [2] | (69,843) | 44,763 |
Ending balance | $ 710,885 | $ 189,543 | |
[1] | The (gains) losses related to the valuation of the convertible notes are included in “Change in fair value of convertible notes and derivatives” in the accompanying consolidated statement of operations. | ||
[2] | The loss (gain) related to the revaluation of our warrant liability is included in “Change in fair value of convertible notes and derivatives” in the accompanying consolidated statement of operations. |
SUMMARY OF ASSUMPTIONS AND THE
SUMMARY OF ASSUMPTIONS AND THE SIGNIFICANT TERMS (Details) - Convertible Notes Payable [Member] | 12 Months Ended | |
Dec. 31, 2021USD ($)Day$ / shares | Dec. 31, 2020USD ($)Day$ / shares | |
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Face Amount | $ | $ 762,446 | $ 766,101 |
Minimum [Member] | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Conversion Price | $ / shares | $ 0.00050 | $ 0.00050 |
Percentage of stock price for look-back period | 50.00% | 50.00% |
Look-back period | Day | 3 | 3 |
Maximum [Member] | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Conversion Price | $ / shares | $ 0.00097 | $ 0.00064 |
Percentage of stock price for look-back period | 60.00% | 60.00% |
Look-back period | Day | 25 | 25 |
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member] | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Long-term debt, measurement input | 8 | 8 |
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member] | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Long-term debt, measurement input | 10 | 10 |
Measurement Input, Default Interest Rate [Member] | Minimum [Member] | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Long-term debt, measurement input | 20 | 20 |
Measurement Input, Default Interest Rate [Member] | Maximum [Member] | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Long-term debt, measurement input | 24 | 24 |
FAIR VALUE MEASUREMENTS (Detail
FAIR VALUE MEASUREMENTS (Details Narrative) | Dec. 31, 2021 |
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member] | |
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | |
Warrants outstanding measurement input, percentage | 0.19 |
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member] | |
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | |
Warrants outstanding measurement input, percentage | 0.39 |
Measurement Input, Price Volatility [Member] | Minimum [Member] | |
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | |
Warrants outstanding measurement input, percentage | 273 |
Measurement Input, Price Volatility [Member] | Maximum [Member] | |
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | |
Warrants outstanding measurement input, percentage | 276 |
Measurement Input, Expected Dividend Rate [Member] | |
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | |
Warrants outstanding measurement input, percentage | 0 |
SCHEDULE OF INVENTORIES (Detail
SCHEDULE OF INVENTORIES (Details) - USD ($) | Dec. 31, 2021 | Dec. 31, 2020 |
Inventory Disclosure [Abstract] | ||
Raw Materials | $ 126,349 | $ 78,880 |
Finished Goods | 3,820 | 5,271 |
Total Inventories | 130,169 | 84,151 |
Less: Long-term inventory | (98,880) | (78,880) |
Current portion | $ 31,289 | $ 5,271 |
SCHEDULE OF PROPERTY AND EQUIPM
SCHEDULE OF PROPERTY AND EQUIPMENT (Details) - USD ($) | Dec. 31, 2021 | Dec. 31, 2020 |
Property, Plant and Equipment [Line Items] | ||
Total | $ 266,886 | $ 227,843 |
Less: Accumulated depreciation | (222,185) | (213,101) |
Property and equipment, net | 44,701 | 14,742 |
Computer Equipment [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Total | 25,120 | 25,120 |
Furniture and Fixtures [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Total | 34,757 | 34,757 |
Lab Equipment [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Total | 104,564 | 65,521 |
Telephone Equipment [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Total | 12,421 | 12,421 |
Office Equipment [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Total | 16,856 | 16,856 |
Leasehold Improvements [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Total | $ 73,168 | $ 73,168 |
PROPERTY AND EQUIPMENT (Details
PROPERTY AND EQUIPMENT (Details Narrative) - USD ($) | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Property, Plant and Equipment [Abstract] | ||
Depreciation, Depletion and Amortization, Nonproduction | $ 9,084 | $ 3,831 |
DUE TO_FROM OFFICER (Details Na
DUE TO/FROM OFFICER (Details Narrative) - USD ($) | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Related Party Transaction [Line Items] | ||
Due to officer | $ 199,726 | $ 200,837 |
Repayment of officers loans | 182,741 | 22,150 |
Loans from officer | 105,780 | 254,000 |
Accrued interest expense for amount due to officer | 7,520 | 7,675 |
Rik Deitsch [Member] | ||
Related Party Transaction [Line Items] | ||
Due to officer | $ 199,726 | $ 200,837 |
Debt Instrument, Interest Rate, Stated Percentage | 4.00% | 4.00% |
Repayment of officers loans | $ 182,741 | $ 22,150 |
Loans from officer | 105,780 | 254,000 |
Accrued interest expense for amount due to officer | 7,520 | 7,675 |
Bad debt expense | $ 68,330 | 161,500 |
Company other receivable reserves | $ 402,970 |
SCHEDULE OF DEBT (Details)
SCHEDULE OF DEBT (Details) - USD ($) | Dec. 31, 2021 | Dec. 31, 2020 |
Debt Disclosure [Abstract] | ||
Notes payable – Unrelated third parties (Net of discount of $0 and $1,500, respectively) (2) | $ 1,135,257 | $ 1,346,057 |
Convertible notes payable – Unrelated third parties (Net of discount of $283,429 and $101,448, respectively) (3) | 3,751,760 | 1,276,902 |
Convertible notes payable, at fair value (4) | 2,855,709 | 1,832,439 |
Other advances from an unrelated third party (5) | 225,000 | 225,000 |
SBA notes payable(6) | 149,900 | 214,795 |
Ending balances | 8,117,626 | 4,895,193 |
Less: Long-term portion-Convertible Notes payable-Unrelated third parties | (369,401) | (48,477) |
Less: Long-term portion- SBA notes payable | (147,779) | (204,070) |
Current portion | $ 7,600,446 | $ 4,642,646 |
SCHEDULE OF DEBT (Details) (Par
SCHEDULE OF DEBT (Details) (Parenthetical) - USD ($) | Jun. 24, 2021 | Jun. 02, 2021 | Apr. 26, 2021 | Mar. 03, 2021 | Feb. 25, 2021 | Oct. 05, 2020 | Sep. 21, 2020 | Feb. 18, 2020 | Jan. 21, 2020 | Oct. 31, 2020 | Aug. 31, 2020 | Dec. 31, 2019 | Apr. 30, 2017 | Dec. 31, 2021 | Dec. 31, 2020 |
Short-term Debt [Line Items] | |||||||||||||||
Fair Value Adjustment of Warrants | $ 16,500 | $ 38,500 | |||||||||||||
Conversion of shares, shares | 2,500,000 | 5,700,000 | 27,070,000 | 67,380,000 | 137,700,000 | 107,817,770 | 107,133,333 | 250,000,000 | 250,000,000 | ||||||
Conversion of shares, amount | $ 16,250 | $ 35,340 | $ 192,197 | $ 599,682 | $ 1,500,930 | $ 64,691 | $ 171,413 | $ 275,000 | $ 150,000 | ||||||
Convertible Notes Payable [Member] | Warrant [Member] | |||||||||||||||
Short-term Debt [Line Items] | |||||||||||||||
Debt discount | $ 1,650 | $ 7,550 | |||||||||||||
Number of Warrants | 36,300,000 | 92,100,000 | 44,000,000 | ||||||||||||
Fair Value Adjustment of Warrants | $ 16,500 | $ 38,500 | $ 7,370 | $ 195,178 | $ 123,900 | ||||||||||
Warrants and Rights Outstanding, Maturity Date | October, 2022 | August, 2022 | August, 2020 | ||||||||||||
Note Payable [Member] | |||||||||||||||
Short-term Debt [Line Items] | |||||||||||||||
Debt discount | 0 | 1,500 | |||||||||||||
Convertible Notes Payable [Member] | |||||||||||||||
Short-term Debt [Line Items] | |||||||||||||||
Debt discount | $ 283,429 | $ 101,448 | |||||||||||||
Conversion of shares, shares | 2,500,000 | 5,700,000 | 27,070,000 | 67,380,000 | 137,700,000 | 107,817,770 | 107,133,333 | ||||||||
Conversion of shares, amount | $ 16,250 | $ 35,340 | $ 192,197 | $ 599,682 | $ 1,500,930 | $ 64,691 | $ 171,413 | ||||||||
Promissory Note Two [Member] | |||||||||||||||
Short-term Debt [Line Items] | |||||||||||||||
Repayments of notes payable | $ 25,000 |
SCHEDULE OF FUTURE MINIMUM PRIN
SCHEDULE OF FUTURE MINIMUM PRINCIPAL PAYMENT (Details) - USD ($) | Dec. 31, 2021 | Dec. 31, 2020 |
Short-term Debt [Line Items] | ||
Current portion | $ 7,600,446 | $ 4,642,646 |
Economic Injury Disaster Loan [Member] | ||
Short-term Debt [Line Items] | ||
2022 | 2,121 | |
2023 | 3,283 | |
2024 | 3,408 | |
2025 | 3,538 | |
2026 | 3,673 | |
Thereafter | 133,877 | |
Total | 149,900 | |
Less: Long-term portion - SBA notes payable | (147,779) | |
Current portion | $ 2,121 |
DEBTS (Details Narrative)
DEBTS (Details Narrative) - USD ($) | Jan. 02, 2022 | Jun. 24, 2021 | Jun. 02, 2021 | Apr. 26, 2021 | Mar. 03, 2021 | Feb. 25, 2021 | Oct. 22, 2020 | Oct. 05, 2020 | Sep. 21, 2020 | Mar. 31, 2020 | Feb. 18, 2020 | Jan. 21, 2020 | Feb. 15, 2019 | Sep. 26, 2016 | Mar. 19, 2014 | Aug. 02, 2011 | Oct. 31, 2021 | Aug. 31, 2021 | Jun. 30, 2021 | Apr. 30, 2021 | Mar. 31, 2021 | Feb. 28, 2021 | Nov. 30, 2020 | Oct. 31, 2020 | Oct. 30, 2020 | Sep. 30, 2020 | Aug. 31, 2020 | Jul. 31, 2020 | Jun. 30, 2020 | May 31, 2020 | Mar. 31, 2020 | Feb. 29, 2020 | Jan. 31, 2020 | Dec. 31, 2019 | Nov. 30, 2019 | Sep. 30, 2019 | Jun. 30, 2019 | Feb. 28, 2019 | Jan. 31, 2019 | Sep. 30, 2018 | Aug. 31, 2018 | Jul. 31, 2018 | Jun. 30, 2018 | Mar. 31, 2018 | Nov. 30, 2017 | Oct. 31, 2017 | Jul. 31, 2017 | Jun. 30, 2017 | May 31, 2017 | Apr. 30, 2017 | Oct. 31, 2016 | Aug. 31, 2016 | Jul. 31, 2016 | Jun. 30, 2016 | May 31, 2016 | Apr. 30, 2016 | Jun. 30, 2012 | Mar. 31, 2021 | Mar. 31, 2020 | Mar. 31, 2014 | Mar. 31, 2012 | Jun. 30, 2021 | Sep. 30, 2021 | Dec. 31, 2021 | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2012 | Dec. 31, 2010 | Sep. 30, 2023 | Aug. 31, 2022 | Feb. 28, 2022 | May 31, 2019 | Mar. 31, 2016 | Aug. 31, 2013 | Dec. 31, 2011 |
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Principal balance | $ 101,818 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued interest | $ 10,000 | $ 147,768 | $ 147,768 | $ 179,522 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | 1,135,257 | 1,135,257 | 1,346,057 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued, amount | 200,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued interest | 21,023 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Amortization of debt | 326,391 | 130,485 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt conversion, amount | $ 16,250 | $ 35,340 | $ 192,197 | $ 599,682 | $ 1,500,930 | $ 64,691 | $ 171,413 | $ 275,000 | $ 150,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt conversion, shares issued | 2,500,000 | 5,700,000 | 27,070,000 | 67,380,000 | 137,700,000 | 107,817,770 | 107,133,333 | 250,000,000 | 250,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable - Unrelated third parties | 3,751,760 | 3,751,760 | 1,276,902 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from convertible debt | 2,288,560 | 527,983 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants, fair value | $ 16,500 | $ 38,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Repayments of convertible debt | 67,302 | 5,782 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock issued | 2,344,399 | 801,104 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt, Fair Value Disclosures | 2,855,709 | 2,855,709 | 1,832,439 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from related party | 105,780 | 254,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
University Centre West Ltd [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Payments for rent | $ 55,410 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Payable [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | 0 | 0 | 1,500 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Promissory Note One [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest rate | 10.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued interest | 5,783 | 5,783 | 4,769 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from debt | $ 10,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Promissory Note Two [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest rate | 2.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued interest | 74,334 | 74,334 | 62,167 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | 50,000 | 50,000 | 50,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from debt | $ 75,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Promissory Note Two [Member] | Common Stock [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued, shares | 5,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Promissory Note Three [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest rate | 2.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued interest | 67,534 | 67,534 | 55,367 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | 50,000 | 50,000 | 50,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from debt | $ 50,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Promissory Note Four [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest rate | 2.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | 333,543 | 333,543 | 333,543 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from debt | $ 333,543 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued interest | 187,673 | 187,673 | 167,216 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Promissory Note Four [Member] | Common Stock [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued, shares | 20,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | $ 5,895 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock issued, reverse stock splits | 10,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued, amount | $ 6,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Promissory Note Five [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest rate | 10.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued interest | $ 15,900 | 1,371 | 1,371 | 1,371 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | 60,000 | 15,000 | 15,000 | 15,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from debt | $ 75,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt settlement amount | $ 15,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Promissory Note Six [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest rate | 2.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued interest | 63,834 | 63,834 | 51,667 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from debt | $ 50,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Promissory Note Seven [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest rate | 10.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued interest | 5,750 | 5,750 | 4,483 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from debt | $ 12,500 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Promissory Note Eight [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest rate | 15.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | 33,874 | 33,874 | 48,250 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from debt | $ 200,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt settlement amount | 33,874 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Repayment of debt settlement amount | $ 130,401 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Repayments of debt | 14,376 | 44,478 | $ 42,698 | 34,976 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Promissory Note Eight [Member] | One Unrelated Third Parties [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt settlement amount | $ 130,401 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Repayments of debt | 5,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Promissory Note Eight [Member] | Two Unrelated Third Parties [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt settlement amount | 40,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Repayments of debt | $ 2,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Promissory Note Nine [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | $ 50,000 | $ 50,000 | 50,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | 10,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from debt | $ 50,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Promissory Note Ten [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Principal balance | $ 33,000 | 29,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest rate | 12.00% | 12.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | 6,000 | $ 6,000 | 1,500 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from debt | $ 36,000 | $ 36,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Repayments of debt | 1,000 | 6,500 | 5,000 | 7,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, periodic payment | $ 1,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | 3,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Amortization of debt | 1,500 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt conversion, amount | $ 30,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt conversion price | $ 0.01 | $ 0.01 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Promissory Note Eleven [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Principal balance | $ 16,693 | $ 166,926 | $ 166,926 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest rate | 2.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued interest | 23,258 | $ 18,701 | $ 12,149 | 18,917 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | 166,926 | 183,619 | 166,926 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | 16,693 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from debt | 148,225 | $ 60,000 | $ 76,076 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt fair value | 73,032 | 343,056 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt settlement amount | 16,693 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Amortization of debt | $ 16,693 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt conversion price | $ 0.002 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument interest rate, during period | 2.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gain on settlement of debt | $ 56,339 | $ 319,798 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Promissory Note Eleven [Member] | Common Stock [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued, shares | 20,866,250 | 29,072,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Promissory Note Twelve [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued, shares | 125,000,000 | 10,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | 84,000 | $ 70,000 | $ 84,000 | 84,000 | 84,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | 20,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from debt | 120,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt settlement amount | $ 50,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued, amount | $ 87,500 | 32,200 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | $ 14,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gain on settlement of debt | $ 37,500 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt conversion, shares issued | 36,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Promissory Note Thirteen [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued interest | 2,000 | 2,000 | 2,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | 18,000 | 18,000 | 18,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | $ 3,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from debt | $ 18,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Principal balance | 3,751,760 | 3,751,760 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | 283,429 | 283,429 | 101,448 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | 283,430 | 283,430 | 101,448 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Amortization of debt | 308,200 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt conversion, amount | $ 16,250 | $ 35,340 | $ 192,197 | $ 599,682 | $ 1,500,930 | $ 64,691 | $ 171,413 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt conversion, shares issued | 2,500,000 | 5,700,000 | 27,070,000 | 67,380,000 | 137,700,000 | 107,817,770 | 107,133,333 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total, debt discount | 283,430 | 283,430 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable | 1,836,904 | 1,836,904 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Two Convertible Debentures [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest rate | 8.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, maturity date | Mar. 19, 2018 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued interest | 11,412 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | 27,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt fair value | $ 1,000,000 | $ 30,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Repayments of debt | 3,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gain on settlement of debt | $ 38,412 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from convertible debt | $ 500,000 | $ 1,000,000 | $ 15,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Promissory Note [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued, shares | 20,866,250 | 2,000,000 | 11,000,000 | 29,072,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | $ 183,619 | $ 4,000 | $ 6,000 | $ 166,926 | $ 6,000 | 60,000 | 60,000 | 60,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | 16,693 | 12,000 | 11,000 | 10,000 | 11,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from debt | $ 60,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued, amount | 73,032 | 15,200 | 104,500 | 343,056 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued interest | $ 23,258 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable One [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | 1,650 | 7,550 | $ 62,950 | $ 5,000 | 62,950 | 62,950 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Amortization of debt | 28,421 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from convertible debt | $ 70,000 | 22,000 | $ 618,250 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion price, decrease | $ 0.0003 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion price, increase | $ 0.001 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total, debt discount | $ 255,655 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible debt | 16,500 | 38,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable One [Member] | Warrant [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | $ 16,500 | $ 38,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants, exercise price | $ 0.001 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants, fair value | 195,178 | 123,900 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable Two [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | $ 268,200 | 287,400 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | 7,500 | $ 70,350 | 50,000 | 50,000 | 53,600 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Repayments of debt | 22,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued, amount | 700 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Amortization of debt | 83,720 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt conversion price | $ 0.0005 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from convertible debt | $ 864,225 | 358,800 | $ 555,600 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion price, decrease | $ 0.0008 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion price, increase | $ 0.0002 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total, debt discount | $ 1,276,902 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible debt | $ 57,500 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable | 101,448 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable Two [Member] | Subsequent Event [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible debt | $ 57,500 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable Two [Member] | Warrant [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | 7,500 | 7,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants, exercise price | $ 0.002 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants, fair value | 106,032 | $ 65,634 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants, granted | 71,875,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable Two [Member] | Restricted Shares [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued, shares | 1,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Two Convertible Notes Payable One [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | $ 6,400 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Two Convertible Notes Payable Two [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | 17,370 | 17,370 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | 14,500 | $ 14,500 | 14,500 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Amortization of debt | 17,370 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from convertible debt | $ 159,500 | $ 159,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion price, decrease | $ 0.000275 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion price, increase | $ 0.0002 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total, debt discount | $ 736,180 | 736,180 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Repayments of convertible debt | 10,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable Three [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | $ 112,725 | $ 93,609 | 93,609 | 112,725 | 46,800 | 46,800 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from convertible debt | $ 717,667 | $ 539,351 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion price, decrease | $ 0.0003 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion price, increase | $ 0.002 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable Three [Member] | Subsequent Event [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, maturity date | Aug. 29, 2022 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | $ 228,563 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable Four [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | 22,500 | 22,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from convertible debt | 172,500 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable Four [Member] | Warrant [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | 150,000 | 150,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants, exercise price | $ 0.002 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants, fair value | 409,374 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants, granted | 246,428,571 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable Five [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest rate | 12.00% | 12.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued, shares | 2,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest expense | 2,677 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | $ 30,000 | $ 30,000 | 22,677 | 22,677 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Repayments of debt | 7,323 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, periodic payment | $ 1,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt conversion price | $ 0.01 | $ 0.01 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable Six [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued, shares | 11,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt fair value | 15,200 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt settlement amount | 8,500 | $ 6,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued, amount | 104,500 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gain on settlement of debt | 11,200 | 98,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from convertible debt | 12,000 | 11,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Repayments of convertible debt | 4,500 | 5,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock issued | $ 4,000 | 6,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable Seven [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | $ 166,926 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt conversion price | $ 0.002 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable Seven [Member] | Subsequent Event [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | $ 183,619 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | $ 16,693 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Loans [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | 0 | 0 | $ 22,344 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from related party | $ 225,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Loans One [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Principal balance | 20,000 | 20,000 | 20,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued interest | 21,183 | 21,183 | 17,128 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | $ 20,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt fair value | 84,768 | 84,768 | 69,433 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible debt | $ 120,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Loans Two [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Principal balance | 12,629 | 12,629 | 12,629 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest rate | 20.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, maturity date | May 4, 2018 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued interest | 14,833 | 14,833 | 12,308 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt fair value | 70,418 | 70,418 | 49,875 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from convertible debt | $ 64,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Loans Three [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Principal balance | $ 250,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued interest | 234,417 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | 509,301 | $ 511,319 | 511,319 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt fair value | 1,859,294 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gain on settlement of debt | $ 1,609,294 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Loans Three [Member] | Restricted Shares [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued interest | $ 10,345 | $ 10,140 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued, shares | 107,817,770 | 107,133,333 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | $ 22,000 | $ 22,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Loans Four [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Principal balance | $ 250,000 | $ 250,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest rate terms | We have increased the outstanding principal due by 10% and accrued interest at default interest rate of 24% after the note’s maturity date. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest rate | 8.00% | 8.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued interest | $ 32,657 | $ 32,657 | 3,890 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | 275,000 | 275,000 | 250,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt fair value | 946,639 | 946,639 | 521,370 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative loss | 286,969 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Loans Five [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Principal balance | $ 50,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest rate terms | We have accrued interest at default interest rate of 24% after the note’s maturity date. The Note holder has the right to convert the note into shares of Common Stock at fifty five percent of the average three lowest trading price of our restricted common stock for the fifteen trading days including the date of receipt of conversion notice. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest rate | 8.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued interest | 33,490 | 33,490 | 21,490 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | 50,000 | 50,000 | 50,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt fair value | 202,401 | 202,401 | 146,232 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative loss | $ 46,734 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Loans Six [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Principal balance | $ 20,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest rate terms | We have accrued interest at default interest rate of 24% after the note’s maturity date. The Note holder has the right to convert the note into shares of Common Stock at fifty five percent of the average three lowest trading price of our restricted common stock for the fifteen trading days including the date of receipt of conversion notice. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest rate | 8.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued interest | 12,923 | 12,923 | 11,713 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | 12,923 | 12,923 | 11,713 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt fair value | 79,815 | 79,815 | 57,524 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative loss | $ 17,829 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Loans Seven [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Principal balance | $ 20,000 | $ 60,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued interest | 15,900 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | $ 75,900 | 75,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt fair value | 75,900 | 156,000 | 156,000 | 129,832 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible debt | 55,900 | 55,900 | 55,900 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative loss | $ 75,900 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Loans Seven [Member] | Restricted Shares [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued, shares | 100,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt fair value | $ 140,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock issued | 20,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Loans Eight [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Principal balance | $ 100,000 | $ 1,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued interest | 11,412 | 11,412 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued, shares | 240,350,000 | 500,000,000 | 750,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | 88,917 | 88,917 | 117,572 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from debt | 132,000 | 20,199 | $ 372,374 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt fair value | $ 2,344,399 | $ 425,000 | $ 275,000 | 2,344,399 | 355,668 | 355,668 | 282,173 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Repayments of debt | 40,480 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt conversion price | $ 0.0005 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock issued | 120,175 | $ 175,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative loss | 2,042,612 | 31,205 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Extinguishment of Debt, Amount | 27,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Loans Eight [Member] | Subsequent Event [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | $ 88,917 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Loans Nine [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Principal balance | $ 240,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued, shares | 16,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | 240,000 | 240,000 | 240,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | $ 40,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt fair value | 960,000 | 960,000 | 576,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued, amount | $ 4,688 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Amortization of debt | $ 22,344 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt conversion price | $ 0.0005 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative loss | $ 240,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Paycheck Protection Program Loan [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, term | 24 months | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest rate | 1.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from debt | $ 64,895 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Economic Injury Disaster Loan [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, term | 24 months | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest rate | 3.75% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued interest | 8,906 | 8,906 | 3,660 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from debt | $ 150,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt fair value | 731 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from related party | $ 5,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Loan Agreement [Member] | Note Payable One [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, term | 9 months | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Settlement Agreement [Member] | Liquid Packaging Resources Inc [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | $ 281,772 | $ 175,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Repayments of debt | $ 350,000 | $ 25,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, periodic payment | $ 50,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Penalty for non-payment | $ 25,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sale of stock, shares | 142,858 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock issued, reverse stock splits | 5,714,326 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from settlement | $ 450,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from initial legal settlement | 350,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Penalties on legal settlement | $ 100,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Settlement Agreement [Member] | Southridge Partners LLP [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Business combination, consideration transferred | $ 281,772 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Director [Member] | Loan Agreement [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Principal balance | $ 200,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest rate terms | interest calculated at 10% for the first month plus 12% after 30 days from funding | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest rate | 12.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, maturity date | Dec. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued interest | $ 40,000 | $ 40,000 | $ 40,000 | $ 40,000 | 147,768 | 147,768 | 179,522 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest expense | 18,246 | 19,967 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Director [Member] | Loan Agreement [Member] | Common Stock [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued interest | $ 10,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued, shares | 12,500,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Former Director [Member] | Two Promissory Notes [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Principal balance | $ 101,818 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest rate | 12.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued interest | 21,023 | 51,856 | 51,856 | 40,917 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | $ 91,156 | $ 91,156 | $ 91,156 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from debt | $ 200,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt fair value | $ 100,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt settlement amount | $ 104,000 | $ 88,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gain on settlement of debt | $ 15,500 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Repayment of debt settlement amount | $ 88,500 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt settlement, description | The remaining principal balance of $91,156 and accrued interest of $51,856 is being disputed in court and negotiation for settlement |
SCHEDULE OF COMMON STOCK ISSUED
SCHEDULE OF COMMON STOCK ISSUED FOR CONVERSION OF DEBT (Details) - USD ($) | Jun. 24, 2021 | Jun. 02, 2021 | Apr. 26, 2021 | Mar. 03, 2021 | Feb. 25, 2021 | Oct. 05, 2020 | Sep. 21, 2020 | Feb. 18, 2020 | Jan. 21, 2020 |
Equity [Abstract] | |||||||||
Number of shares converted | 2,500,000 | 5,700,000 | 27,070,000 | 67,380,000 | 137,700,000 | 107,817,770 | 107,133,333 | 250,000,000 | 250,000,000 |
Fair Value of Debt Converted | $ 16,250 | $ 35,340 | $ 192,197 | $ 599,682 | $ 1,500,930 | $ 64,691 | $ 171,413 | $ 275,000 | $ 150,000 |
STOCKHOLDERS_ DEFICIT (Details
STOCKHOLDERS’ DEFICIT (Details Narrative) - USD ($) | Nov. 15, 2021 | Jun. 24, 2021 | Jun. 02, 2021 | Apr. 26, 2021 | Mar. 03, 2021 | Feb. 25, 2021 | Oct. 05, 2020 | Sep. 21, 2020 | Feb. 18, 2020 | Jan. 21, 2020 | Oct. 30, 2017 | Oct. 31, 2021 | Aug. 31, 2021 | Jul. 31, 2021 | Jun. 30, 2021 | Apr. 30, 2021 | Mar. 31, 2021 | Feb. 28, 2021 | Jan. 31, 2021 | Nov. 30, 2020 | Oct. 31, 2020 | Sep. 30, 2020 | Jul. 31, 2020 | Jun. 30, 2020 | Mar. 31, 2020 | Jan. 31, 2020 | Jun. 30, 2019 | Apr. 30, 2019 | Feb. 29, 2020 | Jun. 30, 2021 | Dec. 31, 2021 | Aug. 31, 2018 | Dec. 31, 2021 | Dec. 31, 2020 | Nov. 30, 2021 | Nov. 18, 2021 | Dec. 31, 2018 | Oct. 31, 2017 |
Class of Stock [Line Items] | ||||||||||||||||||||||||||||||||||||||
Common stock, shares authorized | 12,000,000,000 | 12,000,000,000 | 8,000,000,000 | 8,000,000,000 | ||||||||||||||||||||||||||||||||||
Available for distribution, cash per share | $ 0.133 | |||||||||||||||||||||||||||||||||||||
Shares, Issued | 12,500,000 | |||||||||||||||||||||||||||||||||||||
Interest Payable, Current | $ 10,000 | $ 147,768 | $ 147,768 | $ 179,522 | ||||||||||||||||||||||||||||||||||
Fair value of issued shares | $ 200,000 | |||||||||||||||||||||||||||||||||||||
Conversion of shares, shares | 2,500,000 | 5,700,000 | 27,070,000 | 67,380,000 | 137,700,000 | 107,817,770 | 107,133,333 | 250,000,000 | 250,000,000 | |||||||||||||||||||||||||||||
Conversion of shares, amount | $ 16,250 | $ 35,340 | $ 192,197 | $ 599,682 | $ 1,500,930 | $ 64,691 | $ 171,413 | $ 275,000 | $ 150,000 | |||||||||||||||||||||||||||||
Debt instrument accrued interest | 30,850 | |||||||||||||||||||||||||||||||||||||
Debt instrument, face amount | $ 101,818 | |||||||||||||||||||||||||||||||||||||
Notes payable | 1,135,257 | 1,135,257 | 1,346,057 | |||||||||||||||||||||||||||||||||||
Repayment of related party | 182,741 | 22,150 | ||||||||||||||||||||||||||||||||||||
Accrued interest | $ 21,023 | |||||||||||||||||||||||||||||||||||||
Value of shares issued for services | 174,000 | |||||||||||||||||||||||||||||||||||||
Equity Compensation charge | 20,500 | 20,500 | ||||||||||||||||||||||||||||||||||||
Note Payable [Member] | ||||||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||||||||||||||||
Notes payable | $ 50,000 | |||||||||||||||||||||||||||||||||||||
Debt instrument, unamortized discount net issuance costs | 120,000 | |||||||||||||||||||||||||||||||||||||
Original issue discount | $ 20,000 | |||||||||||||||||||||||||||||||||||||
Number of shares issued for settlement of debt | 125,000,000 | |||||||||||||||||||||||||||||||||||||
Related Party Note [Member] | ||||||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||||||||||||||||
Number of shares issued | 5,000,000 | |||||||||||||||||||||||||||||||||||||
Fair value of issued shares | $ 3,000 | |||||||||||||||||||||||||||||||||||||
Repayment of related party | $ 14,400 | |||||||||||||||||||||||||||||||||||||
Seven Convertible Promissory Notes [Member] | ||||||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||||||||||||||||
Conversion of shares, amount | $ 511,319 | |||||||||||||||||||||||||||||||||||||
Note Holder [Member] | ||||||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||||||||||||||||
Number of shares issued | 75,000,000 | |||||||||||||||||||||||||||||||||||||
Fair value of issued shares | $ 45,000 | |||||||||||||||||||||||||||||||||||||
Settlement and Restatement of Promissory Notes[Member] | ||||||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||||||||||||||||
Number of shares issued | 36,000,000 | |||||||||||||||||||||||||||||||||||||
Settlement and Restatement of Promissory Notes[Member] | Revision of Prior Period, Adjustment [Member] | ||||||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||||||||||||||||
Number of shares issued | 10,000,000 | |||||||||||||||||||||||||||||||||||||
Fair value of issued shares | $ 119,700 | |||||||||||||||||||||||||||||||||||||
Promissory Note [Member] | ||||||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||||||||||||||||
Number of shares issued | 20,866,250 | 2,000,000 | 11,000,000 | 29,072,500 | ||||||||||||||||||||||||||||||||||
Fair value of issued shares | $ 73,032 | $ 15,200 | $ 104,500 | $ 343,056 | ||||||||||||||||||||||||||||||||||
Notes payable | 183,619 | 4,000 | 6,000 | 166,926 | $ 60,000 | 60,000 | 60,000 | |||||||||||||||||||||||||||||||
Original issue discount | 16,693 | 12,000 | 11,000 | $ 10,000 | ||||||||||||||||||||||||||||||||||
Repayment of related party | 5,000 | |||||||||||||||||||||||||||||||||||||
Accrued interest | 23,258 | |||||||||||||||||||||||||||||||||||||
Loss on settlement of debt | $ 56,339 | 11,200 | $ 98,500 | $ 319,798 | ||||||||||||||||||||||||||||||||||
Settlement of debt | $ 8,500 | |||||||||||||||||||||||||||||||||||||
Restricted Stock [Member] | Note Holder [Member] | ||||||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||||||||||||||||
Number of shares issued for restricted stock | 25,000,000 | 1,500,000 | 10,000,000 | 1,000,000 | ||||||||||||||||||||||||||||||||||
Repayments of the promissory note | $ 166,926 | $ 84,000 | $ 333,543 | $ 22,000 | ||||||||||||||||||||||||||||||||||
Fair value of restricted shares | $ 107,500 | $ 900 | $ 6,000 | $ 700 | ||||||||||||||||||||||||||||||||||
Note Holder [Member] | ||||||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||||||||||||||||
Conversion of shares, amount | $ 2,344,399 | |||||||||||||||||||||||||||||||||||||
Note Holder [Member] | Third Party [Member] | ||||||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||||||||||||||||
Debt instrument accrued interest | $ 140,000 | |||||||||||||||||||||||||||||||||||||
Debt instrument, face amount | 20,000 | |||||||||||||||||||||||||||||||||||||
Convertible note payable | $ 75,900 | |||||||||||||||||||||||||||||||||||||
Note Holder [Member] | Restricted Stock [Member] | ||||||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||||||||||||||||
Conversion of shares, shares | 107,817,770 | 107,133,333 | 500,000,000 | 240,350,000 | ||||||||||||||||||||||||||||||||||
Conversion of shares, amount | $ 22,000 | $ 22,000 | $ 175,000 | $ 120,175 | ||||||||||||||||||||||||||||||||||
Debt instrument accrued interest | $ 10,345 | $ 10,140 | ||||||||||||||||||||||||||||||||||||
Note Holder [Member] | Restricted Stock [Member] | Third Party [Member] | ||||||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||||||||||||||||
Conversion of shares, shares | 100,000,000 | |||||||||||||||||||||||||||||||||||||
Conversion of shares, amount | $ 20,000 | |||||||||||||||||||||||||||||||||||||
Consultant [Member] | ||||||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||||||||||||||||
Number of shares issued for restricted stock | 30,000,000 | 15,000,000 | 120,000,000 | |||||||||||||||||||||||||||||||||||
Fair value of restricted shares | $ 6,000 | $ 24,000 | ||||||||||||||||||||||||||||||||||||
Number of shares issued for services | 5,000,000 | 25,000,000 | ||||||||||||||||||||||||||||||||||||
Value of shares issued for services | $ 41,000 | $ 100,000 | ||||||||||||||||||||||||||||||||||||
Equity compensation expense | $ 133,000 | $ 8,500 | ||||||||||||||||||||||||||||||||||||
Equity Compensation charge | 20,500 | 20,500 | ||||||||||||||||||||||||||||||||||||
Unrecognized compensation cost | $ 20,500 | $ 20,500 | ||||||||||||||||||||||||||||||||||||
Consultant [Member] | 30 days Through November 2021 [Member] | ||||||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||||||||||||||||
Number of shares issued for services | 25,000,000 | |||||||||||||||||||||||||||||||||||||
Consultant [Member] | Execution of Agreement [Member] | ||||||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||||||||||||||||
Number of shares issued for services | 5,000,000 | |||||||||||||||||||||||||||||||||||||
Value of shares issued for services | $ 33,000 | |||||||||||||||||||||||||||||||||||||
Series A Preferred Stock [Member] | ||||||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||||||||||||||||
Preferred Stock, Shares Authorized | 20,000,000 | 0 | 0 | 20,000,000 | ||||||||||||||||||||||||||||||||||
Number of shares issued | 3,000,000 | |||||||||||||||||||||||||||||||||||||
Preferred Stock, Par or Stated Value Per Share | $ 0.001 | $ 0.001 | $ 0.001 | |||||||||||||||||||||||||||||||||||
Series A Preferred Stock Convertible Series B Preferred Stock [Member] | Board of Directors [Member] | ||||||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, Conversion of Convertible Securities | 3,000,000 | |||||||||||||||||||||||||||||||||||||
Series B Preferred Stock [Member] | ||||||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||||||||||||||||
Preferred Stock, Shares Authorized | 20,000,000 | 20,000,000 | 0 | |||||||||||||||||||||||||||||||||||
Number of shares issued | 12,000,000 | |||||||||||||||||||||||||||||||||||||
Preferred Stock, Par or Stated Value Per Share | $ 0.001 | $ 0.001 | $ 0.001 | $ 0.001 | ||||||||||||||||||||||||||||||||||
Shares, Issued | 9,000,000 | |||||||||||||||||||||||||||||||||||||
Accrued Salaries | $ 540,000 | |||||||||||||||||||||||||||||||||||||
Series B Preferred Stock [Member] | Board of Directors [Member] | ||||||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||||||||||||||||||||
Preferred Stock, Shares Authorized | 3,000,000 |
SCHEDULE OF WARRANTS ISSUED (De
SCHEDULE OF WARRANTS ISSUED (Details) - USD ($) | 1 Months Ended | |
Oct. 31, 2020 | Aug. 31, 2020 | |
Share-based Payment Arrangement [Abstract] | ||
Number of Warrants | 36,300,000 | 92,100,000 |
Fair value of warrants | $ 16,500 | $ 38,500 |
Month of Expiration | October, 2022 | August, 2022 |
SUMMARY OF WARRANTS OUTSTANDING
SUMMARY OF WARRANTS OUTSTANDING (Details) - $ / shares | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Weighted Average Exercise Price, Warrants, Beginning | $ 0.0017 | |
Weighted Average Exercise Price, Warrants, Ending | $ 0.0017 | $ 0.0017 |
Warrant [Member] | ||
Number of warrants outstanding, Beginning | 202,775,000 | 52,500,000 |
Weighted Average Exercise Price, Warrants, Beginning | $ 0.0017 | $ 0.0028 |
Number of warrants, Exercised | ||
Weighted Average Exercise Price, Warrants, Exercised | ||
Number of warrants, Issued | 410,403,571 | 200,275,000 |
Weighted Average Exercise Price, Warrants, Issued | $ 0.0018 | $ 0.0014 |
Number of warrants, Expired | (166,475,000) | (50,000,000) |
Weighted Average Exercise Price, Warrants, Expired | $ 0.0019 | $ 0.0015 |
Number of warrants outstanding, Ending | 446,703,571 | 202,775,000 |
Weighted Average Exercise Price, Warrants, Ending | $ 0.0017 | $ 0.0017 |
SUMMARY OF FIXED PRICE WARRANTS
SUMMARY OF FIXED PRICE WARRANTS OUTSTANDING (Details) - $ / shares | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Weighted Average Number Outstanding | 446,703,571 | 202,775,000 |
Weighted Average Contractual Life | 8 months 1 day | 11 months 4 days |
Weighted Average Exercise Price | $ 0.0017 | $ 0.0017 |
Minimum [Member] | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Exercise Price | 0.001 | 0.001 |
Maximum [Member] | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Exercise Price | $ 0.002 | $ 0.03 |
STOCK WARRANTS (Details Narrati
STOCK WARRANTS (Details Narrative) - USD ($) | 1 Months Ended | 12 Months Ended | ||||||||||
Oct. 31, 2020 | Aug. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | Jan. 01, 2022 | Nov. 30, 2020 | Feb. 28, 2019 | Dec. 31, 2018 | Mar. 31, 2017 | Mar. 03, 2016 | |
Short-term Debt [Line Items] | ||||||||||||
Notes Payable | $ 1,135,257 | $ 1,346,057 | ||||||||||
Fair value of warrants | $ 16,500 | $ 38,500 | ||||||||||
Debt instrument, face amount | $ 101,818 | |||||||||||
Convertible Notes Payable [Member] | ||||||||||||
Short-term Debt [Line Items] | ||||||||||||
Debt instrument, face amount | $ 1,000,000 | |||||||||||
Two Convertible Notes Payable [Member] | ||||||||||||
Short-term Debt [Line Items] | ||||||||||||
Number of warrants to purchase common stock | 71,875,000 | 71,875,000 | ||||||||||
Warrants price | $ 0.002 | $ 0.002 | ||||||||||
Debt instrument, face amount | $ 57,500 | $ 57,500 | $ 57,500 | |||||||||
Debt instrument, original discount | 7,500 | $ 7,500 | ||||||||||
Three Convertible Notes Payable [Member] | ||||||||||||
Short-term Debt [Line Items] | ||||||||||||
Number of warrants to purchase common stock | 246,428,571 | |||||||||||
Warrants price | $ 0.002 | |||||||||||
Fair value of warrants | $ 409,374 | |||||||||||
Debt instrument, face amount | 172,500 | |||||||||||
Debt instrument, original discount | 22,500 | |||||||||||
One Convertible Notes Payable [Member] | ||||||||||||
Short-term Debt [Line Items] | ||||||||||||
Notes Payable | $ 22,000 | $ 22,000 | ||||||||||
Number of warrants to purchase common stock | 44,000,000 | 44,000,000 | ||||||||||
Warrants price | $ 0.001 | $ 0.001 | ||||||||||
Fair value of warrants | $ 7,370 | |||||||||||
Two Convertible Notes Payable [Member] | ||||||||||||
Short-term Debt [Line Items] | ||||||||||||
Fair value of warrants | 106,032 | 65,634 | ||||||||||
Three-year Warrant [Member] | ||||||||||||
Short-term Debt [Line Items] | ||||||||||||
Notes Payable | $ 80,000 | |||||||||||
Warrants, term | 3 years | |||||||||||
Number of warrants to purchase common stock | 6,000,000 | |||||||||||
Warrants price | $ 0.005 | |||||||||||
Warrants, expiration date | Mar. 30, 2020 | |||||||||||
Five Year Warrant [Member] | ||||||||||||
Short-term Debt [Line Items] | ||||||||||||
Warrants, term | 5 years | |||||||||||
Number of warrants to purchase common stock | 2,500,000 | |||||||||||
Warrants price | $ 0.03 | |||||||||||
Warrants, expiration date | Mar. 3, 2021 | |||||||||||
Fair value of warrants | $ 0 | 9 | ||||||||||
Warrant [Member] | ||||||||||||
Short-term Debt [Line Items] | ||||||||||||
Warrants price | $ 0.002 | |||||||||||
Number of warrants | $ 128,400 | |||||||||||
Warrant [Member] | Convertible Notes Payable [Member] | ||||||||||||
Short-term Debt [Line Items] | ||||||||||||
Number of warrants to purchase common stock | 36,300,000 | 92,100,000 | 44,000,000 | 44,000,000 | ||||||||
Warrants price | $ 0.001 | |||||||||||
Fair value of warrants | $ 16,500 | $ 38,500 | $ 7,370 | $ 195,178 | $ 123,900 | |||||||
Debt instrument, face amount | 16,500 | 38,500 | ||||||||||
Debt instrument, original discount | $ 1,650 | $ 7,550 | ||||||||||
Money Warrants [Member] | ||||||||||||
Short-term Debt [Line Items] | ||||||||||||
Number of warrants to purchase common stock | 128,400,000 |
SCHEDULE OF INCOME TAX EXPENSE
SCHEDULE OF INCOME TAX EXPENSE (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Income Tax Disclosure [Abstract] | ||
Computed “expected” tax expense (benefit) - Federal | $ (2,750,059) | $ (161,529) |
Computed “expected” tax expense (benefit) - State | (569,000) | (33,421) |
Permanent differences and other | 2,783,369 | (145,667) |
Change in valuation allowance | 535,690 | 340,617 |
Provision for income taxes |
SCHEDULE OF DEFERRED INCOME TAX
SCHEDULE OF DEFERRED INCOME TAX ASSETS (Details) - USD ($) | Dec. 31, 2021 | Dec. 31, 2020 |
Income Tax Disclosure [Abstract] | ||
Reserve for prepaid inventory | $ 12,166 | $ 23,573 |
Accrued salary | 267,058 | 362,356 |
Recovery for receivables from officer | (25,979) | |
Net operating loss carryforwards | 10,345,757 | 9,729,342 |
Valuation allowance | (10,624,981) | (10,089,292) |
Net deferred income tax asset |
INCOME TAXES (Details Narrative
INCOME TAXES (Details Narrative) - USD ($) | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Operating Loss Carryforwards [Line Items] | ||
valuation allowances increased | $ 535,690 | $ 340,617 |
Operating Loss Carryforwards | 40,800,000 | |
Expired Between 2023 and 2037 [Member] | ||
Operating Loss Carryforwards [Line Items] | ||
Operating Loss Carryforwards | 34,800,000 | |
Incurred After December 31, 2017 [Member] | ||
Operating Loss Carryforwards [Line Items] | ||
Operating Loss Carryforwards | $ 6,000,000 |
SCHEDULE OF ACCRUED EXPENSES (D
SCHEDULE OF ACCRUED EXPENSES (Details) - USD ($) | Dec. 31, 2021 | Dec. 31, 2020 |
Payables and Accruals [Abstract] | ||
Accrued consulting fees | $ 161,550 | $ 166,900 |
Accrued settlement expenses | 35,000 | |
Accrued payroll taxes | 215,543 | 215,581 |
Accrued interest | 469,040 | 351,830 |
Accrued others | 5,337 | 11,121 |
Total | $ 851,470 | $ 780,432 |
SCHEDULE OF PREPAID EXPENSES (D
SCHEDULE OF PREPAID EXPENSES (Details) - USD ($) | Dec. 31, 2021 | Dec. 31, 2020 |
Prepaid Expenses | ||
Supplier advances for future purchases | $ 294,162 | $ 246,162 |
Reserve for supplier advances | (294,162) | (246,162) |
Net supplier advances | ||
Prepaid professional fees | 65,650 | 10,000 |
Deferred stock compensation | 20,500 | |
Total | $ 86,150 | $ 10,000 |
PREPAID EXPENSES (Details Narra
PREPAID EXPENSES (Details Narrative) - USD ($) | Dec. 31, 2021 | Dec. 31, 2020 |
Prepaid Expenses | ||
Future reserve for purchases | $ 48,000 | $ 21,303 |
Total valuation allowance for prepaid | $ 294,162 | $ 246,162 |
CONVERTIBLE NOTES RECEIVABLE (D
CONVERTIBLE NOTES RECEIVABLE (Details Narrative) - USD ($) | Mar. 10, 2022 | Dec. 31, 2021 | Nov. 30, 2021 | Dec. 31, 2020 | Dec. 31, 2018 |
Short-term Debt [Line Items] | |||||
Debt Instrument, Face Amount | $ 101,818 | ||||
Other Income [Member] | |||||
Short-term Debt [Line Items] | |||||
[custom:AmortizationOfNotesReceivables] | $ 12,980 | ||||
Other Income [Member] | Subsequent Event [Member] | |||||
Short-term Debt [Line Items] | |||||
[custom:AmortizationOfNotesReceivables] | $ 26,950 | ||||
Convertible Notes Payable [Member] | |||||
Short-term Debt [Line Items] | |||||
Debt Instrument, Face Amount | 3,751,760 | ||||
Original issue discount | 283,429 | $ 101,448 | |||
Convertible Notes Payable [Member] | Unrelated Third Party [Member] | |||||
Short-term Debt [Line Items] | |||||
Debt Instrument, Face Amount | $ 286,550 | ||||
Original issue discount | $ 13,070 | $ 26,050 | |||
Debt Instrument, Convertible, Conversion Price | $ 0.01 |
SCHEDULE OF OPERATING LEASE LIA
SCHEDULE OF OPERATING LEASE LIABILITY MATURITY TABLE (Details) - USD ($) | 12 Months Ended | |||
Dec. 31, 2021 | Dec. 31, 2020 | Feb. 28, 2021 | Feb. 28, 2016 | |
Commitments and Contingencies Disclosure [Abstract] | ||||
Operating lease cost | $ 80,396 | $ 89,021 | ||
Short-term lease cost | 18,698 | |||
Total lease cost | 80,396 | 107,719 | ||
Operating ROU Assets | 93,811 | 144,010 | ||
Operating lease obligations, current portion | 77,673 | 82,873 | ||
Operating lease obligations, non-current portion | 60,447 | |||
Total | $ 77,673 | $ 143,320 | ||
Weighted average remaining lease term (in years) - operating leases | 1 year | 1 year 8 months 1 day | ||
Weighted average discount rate-operating leases | 8.00% | 8.00% | ||
Cash paid for amounts included in the measurement of operating lease liabilities | $ 95,846 | $ 98,780 | ||
2022 | 81,080 | |||
Total future lease payments | 81,080 | $ 6,500 | $ 3,200 | |
Less imputed interest | $ 3,407 |
COMMITMENTS AND CONTINGENCIES_2
COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($) | Feb. 15, 2019 | Oct. 12, 2018 | Aug. 01, 2017 | Apr. 12, 2017 | Aug. 26, 2016 | Feb. 28, 2016 | Jul. 31, 2015 | Feb. 28, 2021 | Oct. 31, 2015 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2018 | Dec. 31, 2016 |
Defined Benefit Plan Disclosure [Line Items] | |||||||||||||
Operating lease due | $ 3,200 | $ 6,500 | $ 81,080 | ||||||||||
Lease, description | the lease on a month-to-month basis until May 2020 when it was terminated | The lease calls for monthly payments of approximately $6,500 with a 4% increase each year | |||||||||||
Common stock shares issued | 7,330,985,964 | 6,955,197,214 | 1,000,000 | ||||||||||
Note issued | $ 535,787 | $ 87,500 | |||||||||||
Shares issued, price per share | $ 0.18 | ||||||||||||
Accrued liabilities for commissions, expense and taxes | $ 142,500 | ||||||||||||
Equity compensation charges | $ 31,750 | ||||||||||||
Accrued expenses | $ 19,150 | $ 19,150 | |||||||||||
Share based compensation, shares not yet issued | 1,500,000 | 1,500,000 | |||||||||||
Principal balance | $ 101,818 | ||||||||||||
Accrued interest | $ 21,023 | ||||||||||||
Loss contingency, allegations | The violations alleged against the Company by the SEC include: (a) raising over $920,000 in at least two private placement offerings for which the Company failed to file required registration statements with the SEC; (b) issuing a series of materially false or misleading press releases; (c) making false statements in at least one Form 10-Q; and (d) failing to make required public filings with the SEC to disclose the Company’s issuance of millions of shares of stock. The lawsuit makes additional allegations against Mr. McManus and Mr. Deitsch, including that Mr. McManus acted as a broker without SEC registration and defrauded at least one investor by making false statements about the Company, that Mr. Deitsch engaged in manipulative trades of the Company’s stock by offering to pay more for shares he was purchasing than the amount the seller was willing to take, and that Mr. Deitsch failed to make required public filings with the SEC. The lawsuit seeks both injunctive and monetary relief | ||||||||||||
Consulting Services Agreement [Member] | Restricted Stock [Member] | |||||||||||||
Defined Benefit Plan Disclosure [Line Items] | |||||||||||||
Consulting service term | 5 years | ||||||||||||
Common stock shares issued | 500,000 | ||||||||||||
Debt instrument, interest rate | 8.00% | ||||||||||||
Note issued | $ 50,000 | ||||||||||||
Consultant Agreement [Member] | |||||||||||||
Defined Benefit Plan Disclosure [Line Items] | |||||||||||||
Share-based compensation arrangement by share-based payment | 2,500,000 | ||||||||||||
Consultant Agreement [Member] | Common Stock [Member] | |||||||||||||
Defined Benefit Plan Disclosure [Line Items] | |||||||||||||
Debt instrument periodic payment | $ 3,000 | ||||||||||||
Recepto Pharm Leases [Member] | |||||||||||||
Defined Benefit Plan Disclosure [Line Items] | |||||||||||||
Operating lease due | $ 6,900 | ||||||||||||
Lease, description | ReceptoPharm leases a lab and renewed its operating lease agreement for five years beginning August 1, 2017 for monthly payments of approximately $6,900 with a 5% increase each year | ||||||||||||
Paul Reid et Al [Member] | |||||||||||||
Defined Benefit Plan Disclosure [Line Items] | |||||||||||||
Loss contingency, damages sought, value | $ 315,000 | ||||||||||||
Get Credit Healthy, Inc. and Rik Deitsch [Member] | |||||||||||||
Defined Benefit Plan Disclosure [Line Items] | |||||||||||||
Loss contingency, damages sought, value | $ 100,000 | ||||||||||||
Payments for legal settlements | $ 104,000 | ||||||||||||
CSA 8411, LLC [Member] | |||||||||||||
Defined Benefit Plan Disclosure [Line Items] | |||||||||||||
Loss contingency, damages sought, value | $ 100,000 | ||||||||||||
Accrued interest | $ 51,856 | ||||||||||||
Long-term debt | $ 91,156 |
SUBSEQUENT EVENTS (Details Narr
SUBSEQUENT EVENTS (Details Narrative) - USD ($) | 1 Months Ended | 12 Months Ended | |||||||||||||
Feb. 28, 2022 | Jan. 31, 2022 | Oct. 31, 2021 | Aug. 31, 2021 | Apr. 30, 2021 | Mar. 31, 2021 | Feb. 28, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | Sep. 30, 2023 | Aug. 31, 2022 | Mar. 31, 2022 | Feb. 28, 2019 | Dec. 31, 2018 | Oct. 31, 2017 | |
Subsequent Event [Line Items] | |||||||||||||||
Principal balance | $ 101,818 | ||||||||||||||
Debt instrument increase accrued interest | $ 30,850 | ||||||||||||||
Number of shares issued, value | $ 200,000 | ||||||||||||||
Promissory Note [Member] | |||||||||||||||
Subsequent Event [Line Items] | |||||||||||||||
Original issue discount | $ 16,693 | $ 12,000 | $ 11,000 | $ 10,000 | |||||||||||
Number of shares issued | 20,866,250 | 2,000,000 | 11,000,000 | 29,072,500 | |||||||||||
Number of shares issued, value | $ 73,032 | $ 15,200 | $ 104,500 | $ 343,056 | |||||||||||
Subsequent Event [Member] | Restatement of Promissory Note [Member] | |||||||||||||||
Subsequent Event [Line Items] | |||||||||||||||
Principal balance | $ 183,619 | ||||||||||||||
Original issue discount | $ 16,693 | ||||||||||||||
Debt instrument increase accrued interest | $ 16,693 | ||||||||||||||
Number of shares issued | 20,866,250 | ||||||||||||||
Number of shares issued, value | $ 54,252 | ||||||||||||||
Other income | 37,559 | ||||||||||||||
Restated debt balance | 183,619 | ||||||||||||||
Subsequent Event [Member] | Non-related Party [Member] | Promissory Note [Member] | |||||||||||||||
Subsequent Event [Line Items] | |||||||||||||||
Due from related party | $ 199,000 | ||||||||||||||
Debt instrument interest rate stated percentage | 63.76% | ||||||||||||||
Origination fees | $ 4,975 | ||||||||||||||
Convertible Notes Payable [Member] | |||||||||||||||
Subsequent Event [Line Items] | |||||||||||||||
Principal balance | $ 1,000,000 | ||||||||||||||
Convertible Notes Payable [Member] | Minimum [Member] | |||||||||||||||
Subsequent Event [Line Items] | |||||||||||||||
Debt conversion price | $ 0.00050 | $ 0.00050 | |||||||||||||
Convertible Notes Payable [Member] | Maximum [Member] | |||||||||||||||
Subsequent Event [Line Items] | |||||||||||||||
Debt conversion price | $ 0.00097 | $ 0.00064 | |||||||||||||
Convertible Notes Payable [Member] | Subsequent Event [Member] | |||||||||||||||
Subsequent Event [Line Items] | |||||||||||||||
Principal balance | $ 6,000 | ||||||||||||||
Conversion of Stock, Shares Issued | 12,000,000 | ||||||||||||||
Conversion of Stock, Amount Issued | $ 36,000 | ||||||||||||||
Convertible Notes Payable [Member] | Subsequent Event [Member] | Unrelated Third Parties [Member] | |||||||||||||||
Subsequent Event [Line Items] | |||||||||||||||
Principal balance | $ 225,000 | ||||||||||||||
Original issue discount | $ 75,000 | ||||||||||||||
Convertible Notes Payable [Member] | Subsequent Event [Member] | Unrelated Third Parties [Member] | Minimum [Member] | |||||||||||||||
Subsequent Event [Line Items] | |||||||||||||||
Debt conversion price | $ 0.0005 | ||||||||||||||
Convertible Notes Payable [Member] | Subsequent Event [Member] | Unrelated Third Parties [Member] | Maximum [Member] | |||||||||||||||
Subsequent Event [Line Items] | |||||||||||||||
Debt conversion price | $ 0.0008 | ||||||||||||||
Convertible Notes Payable [Member] | Forecast [Member] | |||||||||||||||
Subsequent Event [Line Items] | |||||||||||||||
Principal balance | $ 88,917 |